Inhibitors of cyclin-dependent kinase 7 (CDK7)

ABSTRACT

The present invention provides various compositions, including compounds of Formula (I) or (Ia), or a species thereof, and pharmaceutically acceptable salts, solvates (e.g., hydrates), stereoisomer, tautomers, isotopic and other specified forms thereof. Also provided are methods (or uses) and kits involving the compounds or pharmaceutically acceptable compositions containing them for treating or preventing a disease (e.g., a proliferative disease such as cancer) in a subject. Administration of a compound or pharmaceutical composition described herein is expected to inhibit cyclin-dependent kinase 7 (CDK7), and thereby, induce apoptosis in tumor cells in the subject.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of International application no.PCT/US2019/059542, filed Nov. 1, 2019, which claims the benefit of thefiling date of U.S. provisional application No. 62/754,398, filed Nov.1, 2018; U.S. provisional application No. 62/877,189, filed Jul. 22,2019; U.S. provisional application No. 62/915,983, filed Oct. 16, 2019,and U.S. provisional application No. 62/927,469, filed Oct. 29, 2019.The content of each of these prior applications is hereby incorporatedby reference herein in its entirety.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted electronically in ASCII format and is hereby incorporated byreference in its entirety. The ASCII copy, created on Jan. 30, 2020, isnamed SYR-037_SL.txt and is 992 bytes in size.

BACKGROUND OF THE INVENTION

Members of the cyclin-dependent kinase (CDK) family are believed to playimportant roles in regulating cellular proliferation. The predominanttarget of the inhibitors described herein, CDK7, exists as aheterotrimeric complex in the cytosol and also forms the kinase core ofthe RNA polymerase (RNAP) II general transcription factor complex in thenucleus. Within that complex, CDK7 phosphorylates the C-terminal domain(CTD) of RNAP II, which is a requisite step in initiating genetranscription.

SUMMARY OF THE INVENTION

The present invention provides selective CDK7 inhibitors that arechemical compounds having a formula disclosed herein (e.g., Formula (I)or a subgenus (e.g., Formula (Ia)) or species thereof) and, in variousembodiments, pharmaceutically acceptable salts, solvates (e.g.,hydrates), stereoisomers or mixtures of stereoisomers (e.g., racemicmixtures), tautomers, and isotopic forms (e.g., deuterated forms)thereof, wherein various component parts of the compounds (e.g.,elements R¹, R², R³, and R⁴ of Formula (I) and subvariables thereof) areas described herein. Compounds of the invention demonstrate surprisingand unexpected superiority over other, comparator compounds in terms ofselectivity for CDK7 over each of CDK2, CDK9 and CDK12; affinity forCDK7/cyclin H complexes; and anti-proliferative activity in cell linemodels, including a cell line model of triple-negative breast cancer. Inaddition, compounds of the invention demonstrate good bioavailability ina rat model. Accordingly, in a first embodiment, the present inventionprovides a compound of Formula (I) or (Ia) or species thereof; in asecond embodiment, the invention provides a salt thereof; in a thirdembodiment, the invention provides a solvate thereof; in a fourthembodiment, the invention provides a stereoisomer thereof of a mixtureof stereoisomers (e.g., a racemic mixture); in a fifth embodiment, theinvention provides a tautomer thereof; and in a sixth embodiment, theinvention provides an isotopic form thereof. We may refer to these formsof a compound (i.e., to the salt form, a solvate, stereoisomer,tautomer, or isotopic form) as “specified forms” of the compound. Alsowithin the meaning of “specified form” are forms of a compound thatmanifest a combination of the attributes, features, or properties of asalt, solvate, stereoisomer, tautomer, or isotopic form. For example,the methods and uses of the invention can be carried out with a saltthat has been solvated (e.g., a hydrated) or a salt of a stereoisomer,tautomer, or isotopic form of a compound of Formula I, I(a), or aspecies thereof; with a solvate (e.g., hydrate) containing a salt,stereoisomer, tautomer, or isotopic form of a compound of Formula I,I(a), or a species thereof; with a stereoisomer of a compound of FormulaI, or a species thereof, that is in the form of a salt or solvate (e.g.,hydrate) or is a tautomer or isotopic form of a compound of Formula I,or a species thereof; with a tautomer of a compound of Formula I, I(a),or a species thereof that is in the form of a salt or solvate (e.g.,hydrate) or that is a stereoisomer or isotopic form of a compound ofFormula I, I(a), or a species thereof; or with an isotopic form of acompound of Formula I, I(a), or a species thereof that is a salt,solvate (e.g., hydrate), stereoisomer, or tautomer of a compound ofFormula I, I(a), or a species thereof. Any of these specified forms canbe pharmaceutically acceptable and/or contained within apharmaceutically acceptable composition (e.g., formulated for oraladministration). For example, a salt of a compound can be solvated; astereoisomer can be solvated; a tautomer can be in a salt form and/orinclude isotopes; etc. Thus, the invention encompasses, as a specifiedform, salts of the compound per se as well as salts of the stereoisomer,tautomeric, and isotopic forms of the compound. Similarly, and in caseof doubt, either a given compound or a specified form thereof can besolvated or made as an isotopic form. For example, the inventionencompasses, as specified forms, solvates of the compound per se as wellas solvates of a salt, stereoisomer, tautomer, or isotopic form thereof;the invention encompasses isotopic forms of the compound per se as wellas isotopic forms of the salt, solvate, stereoisomer, or tautomerthereof. These compositions (e.g., salts of a compound, stereoisomer,tautomer, or isotopic form; solvates of a compound, a stereoisomerthereof, tautomer, or isotopic form; isotopic forms of a salt, solvate,stereoisomer, or isomeric form of a compound; and so forth) constitutecompositions of the invention useful as described herein. Accordingly, apharmaceutical composition of the invention, including any of thoseformulated as described further below (e.g., for oral administration),can include a compound described herein or any one or more of thespecified forms thereof. In one embodiment, the invention features acompound of structural Formula (I):

or a pharmaceutically acceptable salt, solvate, stereoisomer or mixtureof stereoisomers, tautomer, or isotopic form thereof, wherein R¹ ismethyl or ethyl; R² is methyl or ethyl; R³ is 5-methylpiperidin-3-yl,5,5-dimethylpiperidin-3-yl, 6-methylpiperidin-3-yl, or6,6-dimethylpiperidin-3-yl, wherein one or more hydrogen atoms in R³ isoptionally replaced by deuterium; and R⁴ is —CF₃ or chloro. Morespecifically, in a compound of Formula (I) or in the pharmaceuticallyacceptable salt, solvate, stereoisomer or mixture of stereoisomers,tautomer, isotopic form, or other specified form thereof (i) R¹ ismethyl and R² is methyl or (ii) R¹ is methyl and R² is ethyl. In otherembodiments, R¹ is ethyl and R² is ethyl. In some aspects of any one ofthese embodiments, R⁴ is —CF₃. In other aspects of any one of theseembodiments, R⁴ is chloro. In various aspects of any of the precedingembodiments, R³ is 5-methylpiperidin-3-yl, R³ is5,5-dimethylpiperidin-3-yl, R³ is 6-methyl-piperidin-3-yl, or R³ is6,6-dimethylpiperidin-3-yl, wherein one or more hydrogen atoms in R³ isoptionally replaced by deuterium. A compound of Formula (I) can havestructural Formula (Ia):

and the invention encompasses pharmaceutically acceptable salts,solvates (e.g., hydrates), tautomers, isotopic forms, or other specifiedforms of a compound of Formula (Ia), wherein R³ is

More specifically, in a compound of Formula (Ia) or a pharmaceuticallyacceptable salt, solvate, tautomer, isotopic form, or other specifiedform thereof (i) R¹ is methyl and R² is methyl or (ii) R¹ is methyl andR² is ethyl. In other embodiments, R¹ is ethyl and R² is ethyl. In someembodiments, in a compound of Formula (Ia) or a specified form thereof,R⁴ is —CF₃. In other embodiments, in a compound of Formula (Ia) or aspecified form thereof, R⁴ is chloro. In some embodiments, a compound ofFormula (I) or (Ia) is:

and the invention encompasses pharmaceutically acceptable salts,solvates (e.g., hydrates), tautomers, isotopic forms or other specifiedforms of any one of the three foregoing compounds. In one embodiment,the compound is

or a pharmaceutically acceptable salt thereof. The invention alsoencompasses solvates (e.g., hydrates), tautomers, isotopic forms orother specified forms of the foregoing compound. In isotopic forms, oneor more hydrogen atoms in R³ is replaced with deuterium. In otherembodiments, none of the hydrogen atoms of a compound (e.g., none of thehydrogen atoms in R³) are replaced with deuterium. In other embodiments,the invention features a solvate (e.g., a hydrate) of a compound ofFormula (I), (Ia), or a species thereof, with the elements R¹, R², R³,and R⁴ as described herein. In other embodiments, the invention featuresa solvate (e.g., a hydrate) of a salt of a compound of Formula (I),(Ia), or a species thereof; a solvate (e.g., a hydrate) of a tautomer ofa compound of Formula (I), (Ia), or a species thereof; and a solvate(e.g., a hydrate) of an isomeric form of a compound of Formula (I),(Ia), or a species thereof. The solvate, in any of these embodiments,can be pharmaceutically acceptable and incorporated within apharmaceutical composition, including any of those formulated asdescribed below (e.g., for oral administration).

In another aspect, the invention features a pharmaceutical composition,which we may also refer to as a pharmaceutical formulation, including acompound as described above (i.e., a compound of Formula (I), (Ia), aspecies thereof or a specified form thereof (e.g., a pharmaceuticallyacceptable salt), and a pharmaceutically acceptable carrier.Pharmaceutical compositions of the invention can be formulated for oraladministration and/or formulated in unit dosage form (including, e.g., acompound of Formula (I), (Ia), a species thereof, or a salt thereof).

In another aspect, the invention features methods or “use” of apharmaceutical composition described herein in treating or preventing adisease, wherein the disease is a proliferative disease, inflammatorydisease, autoinflammatory disease, autoimmune disease, or infectiousdisease (each encompassing the specific diseases described herein; see,e.g., the definitions provided herein) in a subject in need thereof.Methods of treatment may include a step of administering apharmaceutical composition and “use” of the present compositions may bein the preparation of a medicament. In one embodiment, the disease is aproliferative disease (e.g., a cancer, benign neoplasm, or pathologicangiogenesis). For example, the cancer can be a blood cancer (e.g., aleukemia (e.g., AML) or lymphoma). In other embodiments, the cancer ischaracterized by the presence of a solid tumor (in, e.g., the breast(e.g., a TNBC, HR+, or other type of breast cancer described herein), GItract (e.g., a CRC), lung (e.g., NSCLC or other type of lung cancerdescribed herein), pancreas, or prostate). In other embodiments, thecancer is a fallopian tube cancer; an ovarian cancer (e.g., a high gradeserous ovarian cancer, epithelial ovarian cancer, or clear cell ovariancancer); a cancer of the central nervous system (e.g., a glioma); amelanoma. or Ewing's sarcoma. In other embodiments, the cancer is apancreatic cancer; a primary peritoneal cancer; prostate cancer;retinoblastoma; or a squamous cell cancer of the head or neck. In oneembodiment, the various methods and uses described herein (e.g., intreating or preventing a proliferative disease, including but notlimited to those just described, an inflammatory disease,autoinflammatory disease, autoimmune disease, or infectious disease) areapplied to a subject who has been determined to have one or more of thefollowing (as determined in, for example, a biological sample of diseasecells obtained from the subject): a high grade cancer (e.g., high gradeserous ovarian cancer (HGSOC) or breast cancer); a cellular phenotype inwhich a steroid receptor is present and/or overexpressed or otherwiseabberent; a triple-negative breast cancer; and/or resistance to apreviously administered chemotherapeutic agent (e.g., a Bcl-2 inhibitorsuch as venetoclax, a BET inhibitor, a CDK4/6 inhibitor such aspalbociclib or ribociclib, a CDK9 inhibitor such as alvocidib, a FLT3inhibitor, a MEK inhibitor such as trametinib, cobimetinib, orbinemetinib (useful in combination with a compound of Formula (I), (Ia),a species thereof or specified form thereof in treating melanoma), aPARP inhibitor, such as olaparib or niraparib, a PI3K inhibitor, such asalpelisib, apitolisib (GDC-0980), idelalisib, copanlisib, duvelisib,pictilisib, or capecitabine (useful in combination with a compound ofFormula (I), (Ia), a species thereof or specified form thereof intreating, e.g., HR+ breast cancer, TNBC, lymphoma (e.g., follicularlymphoma or non-Hodgkin lymphoma), or leukemia (e.g., CLL), an inhibitorof the PI3K/AKT/mTOR pathway (e.g., gedatolisib), a platinum-basedtherapeutic agent such as cisplatin, oxaliplatin, nedaplatin,carboplatin, phenanthriplatin, picoplatin, satraplatin (JM216), ortriplatin tetranitrate (useful in combination with a compound of Formula(I), (Ia), a species thereof or specified form thereof in treating,e.g., a lung cancer such as SCLC or a GI tract cancer such as CRC), aSERM, such as tamoxifen, raloxifene, or toremifene, a steroid receptordegrading agent (e.g., a SERD, such as fulvestrant), or an agent thatinhibits the production of estrogen (e.g., an aromatase inhibitor suchas anastrozole (available as Arimidex®), exemestane (available asAromasin®), and letrozole (available as Femara®). Combination therapiesincluding one or more of these agents (e.g., for a total of two or threeadministered agents) are also within the scope of the invention and arediscussed further herein. For example, in one embodiment, the methodsencompass the use of or administration of a compound of Formula (I),(Ia), a species thereof or a specified form thereof, in combination witha SERD, such as fulvestrant, or an aromatase inhibitor such asletrozole, to treat a cancer (e.g., a breast cancer (e.g., an HR+/ER+breast cancer)) resistant to treatment with a CDK4/6 inhibitor such aspalbociclib or ribociclib. In one embodiment, the methods encompass theuse of or administration of a compound of Formula (I), (Ia), a speciesthereof or a specified form thereof, in combination with a MEKinhibitor, such as trametinib, which can be used in further combinationwith dabrafenib, vemurafenib, or encorafenib.

In another aspect, the invention features kits comprising apharmaceutical composition or formulation described herein andinstructions for use, and, optionally, a “second” agent selected from ananti-proliferative agent, an anti-cancer agent, an immunosuppressantagent, and a pain-relieving agent, including any one or more of thosespecifically disclosed below). The kits can comprise a container with acompound described herein or a specified form thereof (e.g., apharmaceutically acceptable salt, solvate, stereoisomer, tautomer, orisotopic form thereof), or a composition (e.g., a pharmaceuticallyacceptable composition or formulation, as described herein) comprisingthe compound, salt, solvate, stereoisomer, tautomer or isotopic formthereof. In any embodiment of the kit, instructions for use can beincluded, and that use can be in treating a disease described herein(e.g., a blood cancer, a cancer characterized by the presence of a solidtumor (in, e.g., the breast, GI tract (e.g., a CRC), lung (e.g., NSCLC),pancreas, or prostate), or Ewing's sarcoma.

The pharmaceutically acceptable compositions of the invention include acomposition of the invention (e.g., a compound described herein or aspecified form thereof (e.g., a pharmaceutically acceptable salt,solvate (e.g., hydrate), stereoisomer, tautomer, or isotopic formthereof (or another specified form, such as a solvate of a salt of acompound of Formula (I))) and a pharmaceutically acceptable carrier. Incertain embodiments, the pharmaceutical compositions include atherapeutically or prophylactically effective amount of a compound ofFormula (I) or a subgenus (e.g., Formula (Ia)) or species thereof, or aspecified form thereof (e.g., a pharmaceutically acceptable salt,solvate, stereoisomer, tautomer, isotopic form, or other specified formthereof). The pharmaceutical composition may be useful in treatingand/or preventing a proliferative or infectious disease, as describedfurther below. The present invention also provides methods of making andusing the compounds and other compositions described herein (e.g., anyone of the specified forms or pharmaceutical compositions containing acompound of the invention or a specified form thereof) as therapeuticsfor the prevention and/or treatment of diseases associated withoverexpression and/or aberrant activity of CDK7. Amenable diseasesinclude proliferative diseases (e.g., cancers (e.g., a breast cancer, aleukemia or other blood cancer, melanoma, multiple myeloma (MM), ovariancancer, a cancer of the GI tract (e.g., a CRC) or lung (e.g., NSCLC),pancreatic cancer, prostate cancer, or Ewing's sarcoma), benignneoplasms, and pathologic angiogenesis), inflammatory diseases,autoinflammatory diseases, autoimmune diseases, and infectious diseases,as described herein (see, e.g., the definitions).

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a table depicting the inhibitory and dissociation constantsand selectivity of the indicated compounds (three compounds of theinvention and four comparators) against CDK2, CDK7, CDK9, and CDK12.

FIG. 2 is a line graph depicting changes in tumor volume (mm³) over time(days) in the palbociclib-resistant HR+BC PDX model ST1799 (as describedfurther in the Examples below).

FIG. 3 is a line graph depicting changes in tumor volume (mm³) over time(days) in the palbociclib- and fulvestrant-resistant HR+BC PDX modelST941 (as described further in the Examples below).

FIG. 4 is a panel showing three line graphs that depict changes in tumorvolume (mm³) over time (days) in PDX models of TNBC (BR5010; top), smallcell lung cancer (LU5178; middle), and ovarian cancer (OV15398; bottom).The animals were treated with Compound 101 as described in Example 10.Data obtained from vehicle-treated (control) animals is represented byfilled circles (upper traces in each graph). Data from animals modelingTNBC and given 10 mg/kg Compound 101 QD are represented in the top graphby filled squares; the dose of 5 mg/kg BID is represented by triangles.Triangles also represent data obtained from the animal models of SCLCand ovarian cancer treated with Compound 101 in the middle and bottomgraphs.

FIG. 5 is a panel of line graphs showing tumor growth in the PDX modelsindicated and the corresponding isobolograms, each generated asdescribed in Example 11. Compound 101 was applied to cells incombination with the indicated second agents at the concentrationsshown.

FIG. 6 is a panel of graphs generated from the data collected in theCompound 101-treated PDX models described in Example 12. Black lineswith squares represent vehicle-treated animals. Gray lines representCompound 101-treated animals. Error bars are SEM. BID=twice daily;CNV=copy number variation; MPK=mg per kg body weight; PO=oral; QD=oncedaily; RB=retinoblastoma; SCLC=small cell lung cancer; TNBC=triplenegative breast cancer. The dotted line in the graph represents the lastday of treatment.

FIG. 7 is a Table summarizing the TGI values and genetic status of the12 PDX models studied as described in Example 12. Models in the tableare sorted based on highest to lowest response at end of study. BID,CNV, RB, SCLC, and TNBC are as defined for FIG. 6 and elsewhere herein.In case of doubt, CCNE1=cyclin E1; CDKN2A=cyclin-dependent kinaseinhibitor 2A, EoS=end of study, EoT=end of treatment, HGSOC=high-gradeserous ovarian cancer, OVA=ovarian cancer, and TGI=tumor growthinhibition. For the LU5210 model, tissue was not available forconfirmation of RB pathway genetics.

DETAILED DESCRIPTION

The following definitions apply to the compositions, methods, and usesdescribed herein unless the context clearly indicates otherwise, and itis to be understood that the claims may be amended to include languagewithin a definition if needed or desired. Moreover, the definitionsapply to linguistic and grammatical variants of the defined terms (e.g.,the singular and plural forms of a term), and some linguistic variantsare particularly mentioned below (e.g., “administration” and“administering” and “biologically active” and “biological activity”).The chemical elements are identified in accordance with the PeriodicTable of the Elements, CAS version, Handbook of Chemistry and Physics,75^(th) Ed. Additionally, general principles of organic chemistry arewell established and one of ordinary skill in the art can consult, ifdesired, Organic Chemistry by Thomas Sorrell, University Science Books,Sausalito, 1999; Smith and March, March's Advanced Organic Chemistry,5^(th) Edition, John Wiley & Sons, Inc., New York, 2001; Larock,Comprehensive Organic Transformations, VCH Publishers, Inc., New York,1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3^(rd)Edition, Cambridge University Press, Cambridge, 1987.

The term “about,” when used in reference to a value, signifies any valueor range of values that is plus-or-minus 10% of the stated value (e.g.,within plus-or-minus 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9% or 10% of thestated value). For example, a dose of about 10 mg means any dose as lowas 10% less than 10 mg (9 mg), any dose as high as 10% more than 10 mg(11 mg), and any dose or dosage range therebetween (e.g., 9-11 mg;9.1-10.9 mg; 9.2-10.8 mg; and so on). Where a stated value cannot beexceeded (e.g., 100%), “about” signifies any value or range of valuesthat is up to and including 10% less than the stated value (e.g., apurity of about 100% means 90%-100% pure (e.g., 95%-100% pure, 96%-100%pure, 97%-100% pure etc. . . . )). In the event an instrument ortechnique measuring a value has a margin of error greater than 10%, agiven value will be about the same as a stated value when they are bothwithin the margin of error for that instrument or technique.

The term “administration” and variants thereof, such as “administering,”refer to the administration of a compound described herein (e.g., acompound of Formula (I), (Ia), a species thereof or a specified formthereof (e.g., a pharmaceutically acceptable salt thereof), or one ormore additional/second agent(s)), or a composition containing thecompound to a subject (e.g., a human patient) or system (e.g., a cell-or tissue-based system that is maintained ex vivo); as a result of theadministration, the compound or composition containing the compound isintroduced to the subject or system. In addition to compositions of theinvention and second agents useful in combination therapies, items usedas positive controls, negative controls, and placebos, any of which canalso be a compound, can also be “administered.” One of ordinary skill inthe art will be aware of a variety of routes that can, in appropriatecircumstances, be utilized for administration to a subject or system.For example, the route of administration can be oral (i.e., byswallowing a pharmaceutical composition) or may be parenteral. Morespecifically, the route of administration can be bronchial (e.g., bybronchial instillation), by mouth (i.e., oral), dermal (which may be orcomprise topical application to the dermis or intradermal, interdermal,or transdermal administration), intragastric or enteral (i.e., directlyto the stomach or intestine, respectively), intramedullary,intramuscular, intranasal, intraperitoneal, intrathecal, intratumoral,intravenous (or intra-arterial), intraventricular, by application to orinjection into a specific organ (e.g., intrahepatic), mucosal (e.g.,buccal, rectal, sublingual, or vaginal), subcutaneous, tracheal (e.g.,by intratracheal instillation), or ocular (e.g., topical,subconjunctival, or intravitreal). Administration can involveintermittent dosing (i.e., doses separated by various times) and/orperiodic dosing (i.e., doses separated by a common period of time (e.g.,every so many hours, daily (e.g., once daily oral dosing), weekly, twiceper week, etc.)). In other embodiments, administration may involvecontinuous dosing (e.g., perfusion) for a selected time (e.g., about 1-2hours).

The term “angiogenesis” refers to the formation and growth of new bloodvessels. Normal angiogenesis occurs in healthy subjects duringdevelopment and in the context of wound healing. However, patientssuffering from many different disease states, including cancer, diabetes(particularly the progression to blindness associated therewith),age-related macular degeneration, rheumatoid arthritis, and psoriasis,experience excessive and detrimental angiogenesis. Angio-genesis isdetrimental when, e.g., it produces blood vessels that support diseasedcells (e.g., tumor cells), destroy normal tissues (e.g., tissue withinthe eye), or facilitate tumor metastases. We may refer to angiogenesisthat accompanies and/or facilitates a disease state as “pathologicangiogenesis.”

Two events, two entities, or an event and an entity are “associated”with one another if one or more features of the first (e.g., itspresence, level and/or form) are correlated with a feature of thesecond. For example, a first entity (e.g., an enzyme (e.g., CDK7)), geneexpression profile, genetic signature (i.e., a single or combined groupof genes in a cell with a uniquely characteristic pattern of geneexpression), metabolite, or event (e.g., myeloid infiltration)) isassociated with an event (e.g., the onset or progression of a particulardisease), if its presence, level and/or form correlates with theincidence of, severity of, and/or susceptibility to the disease (e.g., acancer disclosed herein). Associations are typically assessed across arelevant population. Two or more entities are physically “associated”with one another if they interact, directly or indirectly, so that theyare and/or remain in physical proximity with one another in a givencircumstance (e.g., within a cell maintained under physiologicalconditions (e.g., within cell culture) or within a pharmaceuticalcomposition). Entities that are physically associated with one anothercan be covalently linked to one another or non-covalently associated by,for example, hydrogen bonds, van der Waals forces, hydrophobicinteractions, magnetism, or combinations thereof. A compound of Formula(I), (Ia), a species thereof, or a specified form thereof (e.g., apharmaceutically acceptable salt) can be non-covalently associated withCDK7.

The term “autoimmune disease” refers to a disease arising from aninappropriate immune response against substances and tissues normallypresent in the body. Stated more simply, a subject's immune systemmistakes some part of the body as a pathogen and attacks its own cells.The attack may be restricted to certain organs (e.g., in autoimmunethyroiditis) or may involve a particular tissue in different places(e.g., Goodpasture's disease affects the basement membrane in both thelung and kidney). Autoimmune diseases include, but are not limited to,ANCA-associated vasculitis (e.g., Wegener's granulomatosis, microscopicpolyangiitis), ankylosing spondylitis, anti-phospholipid antibodysyndrome, autoimmune thyroiditis, cardiomyopathy, Crohn's disease,dermatomyositis or polymyositis, glomerulonephritis, Goodpasture'sdisease, Guillain-Barré disease, Hashimoto's thyroiditis, lymearthritis, lymphadenitis, necrotizing vasculitis, peri-arteritis nodosa,psoriasis, pemphigus vulgaris, psoriatic arthritis, Reiter's syndrome,rheumatoid arthritis, scleroderma, Sjogren's syndrome, systemic lupuserythematosus (SLE), systemic sclerosis, ulcerative colitis, anduveitis. Patients having some autoimmune diseases also experiencesignificant inflammation (e.g., rheumatoid arthritis and SLE) and, so,some diseases can be properly referred to as either an autoimmunedisease or an inflammatory disease.

An “autoinflammatory disease,” which may also be referred to as“periodic fever syndrome,” refers to a disease characterized byrecurrent (episodic) fevers and evidence of systemic inflammation onblood testing (see, e.g., Ciccarelli et al., Curr. Med. Chem.21(3):261-269, 2013). The episodes of inflammation can be intense andaccompanied by rash or joint swelling, and patients are at risk ofamyloidosis, a potentially fatal buildup of a blood protein in vitalorgans. These diseases are distinct from autoimmune disease and do notinvolve auto-reactive T-lymphocytes or auto-antibodies. They include,but are not limited to, Behcet's disease, Blau's Syndrome, chronicrecurrent multifocal osteomyelitis (CRMO) and synovitis acne pustulosishyperostosis osteitis (SAPHO) syndrome, cryopyrin-associated periodicsyndromes (CAPS), deficiency of the interleukin-1 receptor antagonist(DIRA), familial Mediterranean fever (FMF), NLRP12-associatedautoinflammatory disorders, neonatal onset multisystem inflammatorydisease (NOMID), Majeed Syndrome, periodic fever associated withmevalonate kinase deficiency (hyperimmunoglobulin D Syndrome), periodicfever, aphthous stomatitis, pharyngitis and adenopathy syndrome (PFAPA),pyogenic arthritis-pyoderma gangrenosum-acne (PAPA) syndrome,Schnitzier's Syndrome, Sweet's Syndrome, systemic juvenile idiopathicarthritis (sJIA) or Still's Disease and adult-onset Still's Disease(AOSD), and tumor necrosis factor (TNF) receptor-associated periodicsyndrome (TRAPS).

The terms “binding” and variants thereof (such as “bound” and“bind(s)”), particularly when used in reference to two or more entities,refers to a covalent or non-covalent association of the entities (e.g.,a compound and an agent within a pharmaceutical composition or acompound and its target (e.g., CDK7) within a cell). “Direct” bindingoccurs when two entities physically contact one another (e.g., through acovalent or non-covalent chemical bond) while indirect binding occurswhen at least one of the entities physically contacts an intermediateentity that brings the entities into physical proximity with one another(e.g., within a complex). Binding can be assessed in a variety ofcontexts (e.g., in assays in which the entities are fully or partiallyisolated or in more complex, naturally occurring or model systems (e.g.,in a tissue, organ, or cell in vivo or ex vivo)). Assays for binding mayassess biological activity (e.g., the ability of a compound describedherein to inhibit the biological activity of a target (e.g., CDK7)).

The term “biological sample” refers to a sample obtained or derived froma biological source of interest (e.g., a tissue or organism (e.g., ananimal or human patient) or cell culture). For example, a biologicalsample can be a sample obtained from an individual (e.g., a patient oran animal model) suffering from a disease (or, in the case of an animalmodel, a simulation of that disease in a human patient) to be diagnosedand/or treated by the methods of this invention or from an individualserving in the capacity of a reference or control (or whose samplecontributes to a reference standard or control population). Thebiological sample can contain a biological cell, tissue or fluid or anycombination thereof. For example, a biological sample can be or caninclude ascites; blood; blood cells; a bodily fluid, any of which mayinclude or exclude cells (e.g., tumor cells (e.g., circulating tumorcells (CTCs) found in at least blood or lymph vessels)); bone marrow ora component thereof (e.g., hematopoietic cells, marrow adipose tissue,or stromal cells); cerebrospinal fluid (CSF); feces; flexural fluid;free-floating nucleic acids (e.g., circulating tumor DNA); gynecologicalfluids; hair; immune infiltrates; lymph; peritoneal fluid; plasma;saliva; skin or a component part thereof (e.g., a hair follicle);sputum; surgically-obtained specimens; tissue scraped or swabbed fromthe skin or a mucus membrane (e.g., in the nose, mouth, or vagina);tissue or fine needle biopsy samples; urine; washings or lavages such asa ductal lavage or broncheoalveolar lavage; or other body fluids,tissues, secretions, and/or excretions. A biological sample may includecancer cells or immune cells, such as NK cells and/or macrophages, whichare found in many tissues and organs, including the spleen and lymphnodes. Samples of, or samples obtained from, a bodily fluid (e.g.,blood, CSF, lymph, plasma, or urine) may include tumor cells (e.g.,CTCs) and/or free-floating or cell-free nucleic acids. Cells (e.g.,cancer cells) within the sample may have been obtained from anindividual patient for whom a treatment is intended. Samples used in theform in which they were obtained may be referred to as “primary”samples, and samples that have been further manipulated (e.g., byremoving one or more components of the sample) may be referred to as“secondary” or “processed” samples. Such processed samples may containor be enriched for a particular cell type (e.g., a CDK7-expressing cell,which may be a tumor cell), cellular component (e.g., a membranefraction), or cellular material (e.g., one or more cellular proteins,including CDK7, DNA, or RNA (e.g., mRNA), which may encode CDK7 and maybe subjected to amplification).

The term “biologically active” describes an agent (e.g., a compounddescribed herein) that produces an observable biological effect orresult in a biological system or model thereof (e.g., in a human, otheranimal, or a system maintained in cell/tissue culture or in vitro). The“biological activity” of such an agent can manifest upon binding betweenthe agent and a target (e.g., a cyclin-dependent kinase (e.g., CDK7)),and it may result in modulation (e.g., induction, enhancement, orinhibition) of a biological pathway, event, or state (e.g., a diseasestate). For example, the agent can modulate a cellular activity (e.g.,stimulation of an immune response or inhibition of homologousrecombination repair), time spent in a phase of the cell cycle (whichmay alter the rate of cellular proliferation), or initiation ofapoptosis or activation of another pathway leading to cell death (whichmay lead to tumor regression). A biological activity and, optionally,its extent, can be assessed using known methods to detect any givenimmediate or downstream product of the activity or any event associatedwith the activity (e.g., inhibition of cell growth or tumor regression).

The term “cancer” refers to a disease in which biological cells exhibitan aberrant growth phenotype characterized by loss of control of cellproliferation to an extent that will be detrimental to a patient havingthe disease. A cancer can be classified by the type of tissue in whichit originated (histological type) and/or by the primary site in the bodyin which the cancer first developed. Based on histological type, cancersare generally grouped into six major categories: carcinomas; sarcomas;myelomas; leukemias; lymphomas; and mixed types. A cancer treated asdescribed herein may be of any one of these types and may comprise cellsthat are precancerous (e.g., benign), malignant, pre-metastatic,metastatic, and/or non-metastatic. A patient who has a malignancy ormalignant lesion has a cancer. The present disclosure specificallyidentifies certain cancers to which its teachings may be particularlyrelevant, and one or more of these cancers may be characterized by asolid tumor or by a hematologic tumor, which may also be known as ablood cancer (e.g., of a type described herein). Although not allcancers manifest as solid tumors, we may use the terms “cancer cell” and“tumor cell” interchangeably to refer to any malignant cell.

The term “carrier” refers to a diluent, adjuvant, excipient, or othervehicle with which an active pharmaceutical agent (e.g., a compound ofthe invention, or a pharmaceutically acceptable salt, solvate,stereoisomer, tautomer, or isotopic form thereof) is formulated foradministration. The carrier, in the amount and manner incorporated intoa pharmaceutical composition, will be non-toxic to the subject and willnot destroy the biological activity of the active ingredient (e.g., thecompound or other specified form thereof) with which it is formulated.The carrier can be a sterile or sterilizable liquid, such as a water(e.g., water for injection) or a natural or synthetic oil (e.g., apetroleum-based or mineral oil, an animal oil, or a vegetable oil (e.g.,a peanut, soybean, sesame, or canola oil)). The carrier can also be asolid; a liquid that includes one or more solid components (e.g., asalt, for example, a “normal saline”); a mixture of solids; or a mixtureof liquids.

The term “comparable” refers to two or more items (e.g., agents,entities, situations, sets of conditions, etc.) that are not identicalto one another but are sufficiently similar to permit comparisontherebetween so that one of ordinary skill in the art will appreciatethat conclusions may reasonably be drawn based on differences orsimilarities observed. In some embodiments, comparable sets ofconditions, circumstances, individuals (e.g., an individual patient orsubject), or populations are characterized by a plurality ofsubstantially identical features and one or a small number of variedfeatures. One of ordinary skill in the art will understand, in context,what degree of identity is required in any given circumstance for two ormore items to be considered comparable. For example, two items arecomparable to one another when they have in common a sufficient numberand type of substantially identical features to warrant a reasonableconclusion that any differences in results obtained or phenomenaobserved with the items are caused by or are indicative of the variationin those features that are varied. In some embodiments, a comparableitem serves as a “control.” For example, a “control subject/population”can be an untreated (or placebo-treated) individual/population who/thatis afflicted with the same disease as an individual/population beingtreated.

The term “combination therapy” refers to those situations in which asubject is exposed to two or more therapeutic regimens (e.g., two ormore therapeutic agents (e.g., three agents)) to treat a single disease(e.g., a cancer). The two or more regimens/agents may be administeredsimultaneously or sequentially. When administered simultaneously, a doseof the first agent and a dose of the second agent are administered atabout the same time, such that both agents exert an effect on thepatient at the same time or, if the first agent is faster- orslower-acting than the second agent, during an overlapping period oftime. When administered sequentially, the doses of the first and secondagents are separated in time, such that they may or may not exert aneffect on the patient at the same time. For example, the first andsecond agents may be given within the same hour or same day, in whichcase the first agent would likely still be active when the second isadministered. Alternatively, a much longer period of time may elapsebetween administration of the first and second agents, such that thefirst agent is no longer active when the second is administered (e.g.,all doses of a first regimen are administered prior to administration ofany dose(s) of a second regimen by the same or a different route ofadministration, as may occur in treating a refractory cancer). Forclarity, combination therapy does not require that individual agents beadministered together in a single composition or at the same time,although in some embodiments, two or more agents, including a compoundof the invention and a second agent described herein, may beadministered within the same period of time (e.g., within the same hour,day, week, or month).

The term “compound” means a chemical compound (e.g., a compoundrepresented by a structural Formula depicted herein, a sub-genus thereof(e.g., Formula (Ia)), or a species thereof, and any specified formsthereof). Any given compound described herein can be biologically active(e.g., as an inhibitor of CDK7) and may be utilized for a purposedescribed herein, including therapeutic and prophylactic uses (e.g.,when contained in a pharmaceutical composition in a therapeuticallyeffective or prophylactically effective amount, administered to apatient, incorporated into a medicament or into a kit, or otherwise usedas described herein). Two compounds that have the same molecular formulabut differ in the arrangement of their atoms in space are termed“stereoisomers.” The stereoisomers of any referenced or depictedstructure can be enantiomers, which are non-superimposable mirror imagesof each other, or diastereomers, which are not mirror images of eachother (e.g., cis/trans isomers and conformational isomers). Theseinclude the R and S configurations for each asymmetric center, Z and Edouble bond isomers, and Z and E conformational isomers. Compositionscontaining a single type of stereochemical isomer as well asenantiomeric, diastereomeric, and geometric (or conformational) mixturesof the present compounds are within the scope of the invention. Anenantiomer can be characterized by the absolute configuration of itsasymmetric center and is described by the R- and S-sequencing rules ofCahn and Prelog, or by the manner in which the molecule rotates theplane of polarized light and designated as dextrorotatory orlevorotatory (i.e., as (+) or (−)-isomers respectively). A chiralcompound can exist as either individual enantiomer or as a mixturethereof. A mixture containing equal proportions of the enantiomers iscalled a “racemic mixture.”

The terms “dosage form,” “formulation,” and “preparation” refer tocompositions that contain a compound of the invention, or a salt,solvate, stereoisomer, tautomer, isotopic, or other specified formthereof, or to other biologically or therapeutically active ingredientssuitable for use as described herein (e.g., one or more of anadditional/second agent useful in a combination therapy describedherein). The term “unit dosage form” refers to a physically discreteunit of or containing a compound of the invention, or a salt, solvate,stereoisomer, tautomer, isotopic, or other specified form thereof, anyof which can be pharmaceutically acceptable. One or more of anadditional/second agent can also be formulated, administered, or used asdescribed herein in a unit dosage form. Each such unit can contain apredetermined quantity of the active ingredient, which may be the amountprescribed for a single dose (i.e., an amount expected to correlate witha desired outcome when administered as part of a therapeutic orprophylactic regimen) or a fraction thereof (e.g., a unit dosage form(e.g., a tablet or capsule) may contain one half of the amountprescribed for a single dose, in which case a patient would take twounit dosage forms (i.e., two tablets or two capsules)). One of ordinaryskill in the art will appreciate that the total amount of a compositionor agent administered to a particular subject is determined by one ormore attending physicians and may involve administration of multipleunit dosage forms (e.g., as described herein).

The term “dosing regimen” refers to the unit dosage form(s) administeredto, or prescribed for, a subject, and typically includes more than onedose separated by periods of time (e.g., as described herein). Thedosage form(s) administered within a dosing regimen can be of the sameunit dose amount or of different amounts. For example, a dosing regimencan include a first dose in a first dose amount, followed by one or moreadditional doses in a second dose amount that is the same as ordifferent from the first dose amount.

An “effective amount” refers to an amount of an agent (e.g., a compounddescribed herein, whether of the invention or a “second” agent) thatproduces the desired effect for which it is administered. In someembodiments, the term refers to an amount that is sufficient, whenadministered to a population suffering from or susceptible to a diseasein accordance with a therapeutic dosing regimen, to treat the disease,in which case the effective amount may also be referred to as a“therapeutically effective amount.” One of ordinary skill in the artwill appreciate that a therapeutically effective amount may not achievea successful treatment in any particular individual (i.e., in any givenindividual patient). Rather, a therapeutically effective amount providesa desired pharmacological response in a significant or certain number ofsubjects when administered to a population of patients in need of suchtreatment. Where the agent is administered for prophylaxis, the“prophylactically effective amount” provides a desired result (i.e.,delaying the onset of one or more signs or symptoms of a disease) in asignificant or certain number of subjects in a population that does notexhibit signs and/or symptoms of the disease. A reference to aneffective amount may be a reference to an amount of an agentadministered or an amount measured in one or more specific tissues(e.g., a tissue affected by the disease) or fluids (e.g., blood, saliva,urine, etc.) after administration.

The term “hydrate” refers to a compound or a specified form thereof thatis combined with water; as is understood in the art, a hydrate is asolvate in which the solvent is water. The amount of water contained inthe hydrate can be expressed as a ratio of the number of water moleculesto the number of compound molecules. Thus, a hydrate of a compound maybe represented by a general formula such as R˜x H₂O, where R is thecompound and x is a number greater than 0. For example, where x is 1,the hydrate is a monohydrate; where x is 0.5, the hydrate is ahemihydrate; where x is 2, the hydrate is a dihydrate; and where x is 6,the hydrate is a hexahydrate.

“Improve(s),” “increase(s)” or “reduce(s)/decrease(s)” (and obviousvariants thereof, such as “improved” or “improving”) are terms used tocharacterize the manner in which a value changes or has changed relativeto a reference value. For example, a measurement obtained from a patient(or a biological sample obtained therefrom) prior to treatment can beincreased or reduced/decreased relative to that measurement whenobtained during or after treatment in the same patient, a controlpatient, on average in a patient population, or in biological sample(s)obtained therefrom. The value may be improved in either event, dependingon whether an increase or decrease is associated with a positivetherapeutic outcome.

As used herein, the term “inflammatory disease” refers to a diseasecaused by, resulting from, or resulting in inflammation or to adysregulated inflammatory reaction that causes an exaggerated responseby macrophages, granulocytes, and/or T-lymphocytes that leads toabnormal tissue damage and/or cell death. An inflammatory disease can beeither acute or chronic and can result from infectious agents ornon-infectious causes. Inflammatory diseases include, withoutlimitation, acute anaphylaxis, Adult Respiratory Distress Syndrome(ARDS), an allergy, allograft rejection, ankylosing spondylitis,appendicitis, arteriosclerosis, arteritis (e.g., giant cell arteritis),asbestosis, atherosclerosis, asthma, arthritis (e.g., gouty arthritis,degenerative arthritis, inflammatory arthritis, and rheumatoidarthritis), arthrosteitis, an autoimmune disease, berylliosis,blepharitis, bronchiectasis, bronchiolitis, bronchitis (e.g., chronicbronchitis), bursitis, cellular interstitial pneumonia, cellulitis,cervicitis, cholangitis, chorioamnionitis, conjunctivitis, chroniccholecystitis, Crohn's disease, cystic fibrosis, cystitis,dacryoadenitis, delayed-type hypersensitivity reactions (e.g., poisonivy dermatitis), dermatomyositis, desquamative interstitial pneumonia,diabetes (e.g., Type I), encephalitis, endocarditis, endometritis,enteritis, enterocolitis, epicondylitis, epididymitis, extrinsicallergic alveolitis, fasciitis, fibrositis, gastritis, gastroenteritis,giant cell interstitial pneumonia, gingivitis, glomerulonephritis,Goodpasture's disease, Graves' disease, Hashimoto's thyroiditis,hayfever, hepatitis, host-versus-graft rejection, ileitis, immediatehypersensitivity reactions, inflammatory bowel disease (IBD),inflammatory dermatoses, iritis, ischemia (ischemic injury), laryngitis,lymphoid interstitial pneumonia, mixed connective tissue disease,multiple sclerosis, myasthenia gravis, myelitis, myocarditis,necrotizing enterocolitis, nephritis, omphalitis, oophoritis, orchitis,osteitis, osteomyelitis, optic neuritis, otitis, pancreatitis,parotitis, pemphigoid, pemphigus, pericarditis, pernicious anemia,pharyngitis, phlebitis, pleuritis, pneumoconiosis, pneumonia,pneumonitis, polymyalgia rheumatica (PMR), polymyositis, proctitis,progressive systemic sclerosing cholangitis, prostatis, psoriasis,pyelonephritis, reperfusion injury, respiratory tract inflammation,rheumatic fever, rhinitis, salpingitis, sarcoidosis, sclerosis(scleroderma), silicosis, sinusitis, Sjogren's syndrome, stomatitis,synovitis, systemic lupus erythematosus (SLE), talcosis, temporalarteritis, tendonitis, testitis, tonsillitis, transverse myelitis,necrotizing fasciitis, ulcerative colitis, urethritis, urocystitis,usual interstitial pneumonitis (UIP), uvetis, vaginitis, vasculitis,vulvitis, vulvovaginitis, and Wegener's granulomatosis and related formsof angiitis (temporal arteritis and polyarteritis nodosa).

The term “inhibitor” refers to an agent, including a compound describedherein or a specified form thereof, whose presence (e.g., at a certainlevel or in a certain form) correlates with a decrease in the expressionor activity of another agent (i.e., the inhibited agent or target) or adecrease in the occurrence of an event (e.g., cellular proliferation,tumor progression, or metastasis, inflammation, infection, orautoimmunity). In some embodiments, an inhibitor exerts its influence ona target by binding to the target, directly or indirectly, by way ofcovalent bonds or non-covalent association. Inhibition can be assessedin silico, in vitro (e.g., in a cell, tissue, or organ culture orsystem), or in vivo (e.g., in a patient or animal model).

The term “isotopic form” is used to describe a compound that contains atleast one isotopic substitution; the replacement of an isotope of anatom with another isotope of that atom. For example, the substitutioncan be of ²H (deuterium) or ³H (tritium) for ¹H. Thus, we may use theterms “¹H,” “H,” or “hydrogen atom” to refer to the naturally occurringform of hydrogen having a single proton in its nucleus. Othersubstitutions in isotopic forms include ¹¹C, ¹³C or ¹⁴C for ¹²C; ¹³N or¹⁵N for ¹⁴N; ¹⁷O or ¹⁸O for ¹⁶O; ³⁶Cl for ³⁵C; ¹⁸F for ¹⁹F; ¹³¹I for¹²⁷I; etc. . . . . Such compounds have use, for example, as analyticaltools, as probes in biological assays, and/or as therapeutic orprophylactic agents for use in accordance with the present invention. Inparticular, an isotopic substitution of deuterium (²H) for hydrogen mayslow down metabolism, shift metabolism to other sites on the compound,slow down racemization and/or have other effects on the pharmacokineticsof the compound that may be beneficial (e.g., therapeuticallybeneficial).

The terms “neoplasm” and “tumor” are used herein interchangeably andrefer to an abnormal mass of tissue in which the growth of the masssurpasses and is not coordinated with the growth of a normal tissue. Aneoplasm or tumor may be “benign” or “malignant” depending on thefollowing characteristics: the degree of cellular differentiation(including morphology and functionality), rate of growth, localinvasion, and metastasis. A “benign neoplasm” is generally welldifferentiated, has a slower growth rate than a malignant neoplasm, andremains localized to the site of origin (i.e., does not have thecapacity to infiltrate, invade, or metastasize to distant sites). Benignneoplasms include, but are not limited to, acrochordons, adenomas,chondromas, intraepithelial neoplasms, lentigos, lipomas, sebaceoushyperplasias, seborrheic keratoses, and senile angiomas. The benignneoplasm can also be tuberous sclerosis, or tuberous sclerosis complex(TSC) or epiloia (derived from “epilepsy, low intelligence, adenomasebaceum”). Benign neoplasms can later give rise to malignant neoplasms(believed to occur as a result of genetic changes in a subpopulation ofthe tumor's neoplastic cells), and such neoplasms are referred to as“pre-malignant neoplasms.” An exemplary pre-malignant neoplasm is ateratoma. In contrast, a “malignant neoplasm” is generally poorlydifferentiated (anaplasia) and grows rapidly with progressiveinfiltration, invasion, and destruction of surrounding tissue. Malignantneoplasms also generally have the capacity to metastasize to distantsites.

The terms “patient” and “subject” refer to any organism to which acompound described herein, or a specified form thereof, is administeredin accordance with the present invention, e.g., for experimental,prophylactic, and/or therapeutic purposes. Typical subjects includeanimals (e.g., mammals such as mice, rats, rabbits, non-human primates,and humans; domesticated animals, such as dogs and cats; and livestockor any other animal of agricultural or commercial value). In someembodiments, a subject is suffering from a disease (e.g., aproliferative disease, such as cancer) described herein.

A “pharmaceutical composition” or “pharmaceutically acceptablecomposition,” which we may also refer to as a “pharmaceuticalformulation” or “pharmaceutically acceptable formulation,” is acomposition/formulation in which an active agent (e.g., an activepharmaceutical ingredient (e.g., a compound, salt, solvate,stereoisomer, tautomer, or isotopic form thereof)) is formulatedtogether with one or more pharmaceutically acceptable carriers. Theactive agent/ingredient can be present in a unit dose amount appropriatefor administration in a therapeutic regimen that shows a statisticallysignificant probability of achieving a predetermined therapeutic effectwhen administered to a relevant population. The pharmaceuticalcomposition may be specially formulated for administration in solid orliquid form, including such forms made for oral or parenteraladministration. For oral administration, the pharmaceutical compositioncan be formulated, for example, as an aqueous or non-aqueous solution orsuspension or as a tablet or capsule. For systemic absorption throughthe mouth, the composition can be formulated for buccal administration,sublingual administration, or as a paste for application to the tongue.For parenteral administration, the composition can be formulated, forexample, as a sterile solution or suspension for subcutaneous,intramuscular, intravenous, intra-arterial, intraperitoneal,intra-tumoral, or epidural injection. Pharmaceutical compositionscomprising an active agent/ingredient (e.g., a compound described hereinor a specified form thereof) can also be formulated as sustained-releaseformulations or as a cream, ointment, controlled-release patch, or sprayfor topical application. Creams, ointments, foams, gels, and pastes canalso be applied to mucus membranes lining the nose, mouth, vagina, andrectum. Any of the compounds described herein and any pharmaceuticalcomposition containing such a compound may also be referred to as a“medicament.”

The term “pharmaceutically acceptable,” when applied to a carrier usedto formulate a composition disclosed herein (e.g., a pharmaceuticalcomposition), means a carrier that is compatible with the otheringredients of the composition and not deleterious to a patient (e.g.,it is non-toxic in the amount required and/or administered (e.g., in aunit dosage form)).

The term “pharmaceutically acceptable,” when applied to a salt, solvate,stereoisomer, tautomer, or isotopic form of a compound described herein,refers to a salt, solvate, stereoisomer, tautomer, or isotopic form thatis, within the scope of sound medical judgment, suitable for use incontact with the tissues of humans (e.g., patients) and lower animals(including, but not limited to, mice and rats used in laboratorystudies) without unacceptable toxicity, irritation, allergic responseand the like, and that can be used in a manner commensurate with areasonable benefit/risk ratio. Many pharmaceutically acceptable saltsare well known in the art (see, e.g., Berge et al., J. Pharm. Sci.66:1-19, 1977). Pharmaceutically unacceptable salts, solvates,stereoisomers, tautomers or isotopic forms of the present compounds arealso within the scope of the present invention and have utility in, forexample, chemical processes and syntheses and in experiments performedin vitro. In pharmaceutically unacceptable compositions, a compound,salt, solvate, stereoisomer, tautomer, or isotopic form thereof may bepresent in an amount that is too concentrated or too dilute foradministration to a patient.

A “polypeptide” is a polymer of amino acid residues, regardless oflength, source, or post-translational modification; it encompasses butis not limited to full-length, naturally occurring proteins. Where apolypeptide is bound by (e.g., specifically bound) or otherwiseinteracts with a composition described herein, we may refer to thatpolypeptide as the composition's “target.”

The terms “prevent(s),” “prevention,” “prophylaxis/prophylactic,” andthe like, when used in connection with the occurrence of disease (e.g.,a proliferative disease, such as a cancer), refer to reducing the riskof developing the disease and/or to delaying the onset of a sign orsymptom thereof. Prevention can be considered complete when onset hasbeen delayed for a predefined time.

A “proliferative disease” is a disease characterized by an excessiveproliferation of cells. Proliferative diseases are associated with: (1)pathological proliferation of normally quiescent or normallyproliferating cells; (2) pathological migration of cells from theirnormal location (e.g., metastasis of neoplastic cells); (3) pathologicalexpression of proteolytic enzymes such as the matrix metalloproteinases(e.g., collagenases, gelatinases, and elastases), which can lead tounwanted turnover of cellular matrices; and/or (4) pathologicalangiogenesis, as occurs in proliferative retinopathy and tumormetastasis. Exemplary proliferative diseases include cancers, benignneoplasms, and angiogenesis that accompanies and facilitates a diseasestate (defined above as pathologic angiogenesis).

The term “reference” describes a standard or control relative to which acomparison is made. For example, an agent, animal (e.g., a subject(e.g., an animal used in laboratory studies)), cell or cells, individual(e.g., an individual patient), population, sample (e.g., biologicalsample), sequence or value of interest is compared with a reference orcontrol agent, animal (e.g., a subject (e.g., an animal used inlaboratory studies)), cell or cells, individual (e.g., an individualpatient), population, sample, or sequence or value, respectively. Insome embodiments, a reference or control is tested and/or determinedsubstantially simultaneously with the testing or determination ofinterest. In other embodiments, a reference or control is a historicalreference or control, optionally embodied in a tangible medium.Typically, as would be understood by one of ordinary skill in the art, areference or control is determined or characterized under comparableconditions to those under assessment, and one of ordinary skill in theart will appreciate when sufficient similarities are present to justifyreliance on and/or comparison to a particular possible reference orcontrol.

The term “response” with respect to a treatment may refer to anybeneficial alteration in a subject's or patient's condition that occursas a result of, or correlates with, treatment. Such an alteration mayinclude stabilization of the condition (e.g., prevention ofdeterioration that would have taken place in the absence of thetreatment (e.g., stable disease)), amelioration of symptoms of thecondition, and/or improvement in the prospects for cure of the condition(e.g., tumor regression), etc. The response may be a cellular response(e.g., a tumor's response) and can be measured using a wide variety ofcriteria, including clinical criteria and objective criteria, known inthe art. Techniques for assessing a response include, but are notlimited to, assay assessment, clinical examination, positron emissiontomography, X-ray, CT scan, MRI, ultrasound, endoscopy, laparoscopy,assessing the presence or level of tumor markers in a sample obtainedfrom a subject, cytology, and/or histology. Regarding measuring tumorresponse, methods and guidelines for assessing response to treatment arediscussed in Therasse et al. (J. Natl. Cancer Inst., 92(3):205-216,2000). The exact response criteria can be selected by one of ordinaryskill in the art in any appropriate manner, provided that when comparinggroups of cancers and/or patients, the groups to be compared areassessed based on the same or comparable criteria for determiningresponse rate.

The term “solvate” refers to a compound formed by the combination ofmolecules of a solute with molecules of solvent. Solvents that can beused to form a solvate include water, methanol, ethanol, acetic acid,DMSO (dimethyl sulfoxide), THF (tetrahydrofuran), diethyl ether, and thelike. A solvate in which the solvent is water is referred to as ahydrate. A compound can be prepared as a liquid or solid solvate form,e.g., as a crystalline solvate. The solvate can be pharmaceuticallyacceptable and can be either a stoichiometric or non-stoichiometricsolvate. In certain instances, the solvate will be capable of isolation,for example, when one or more solvent molecules are incorporated in thecrystal lattice of a crystalline solid. “Solvate” encompasses bothsolution-phase and isolable solvates, and representative solvatesinclude hydrates, ethanolates, and methanolates.

The term “specific,” as used herein with reference to an agent (e.g., acompound) having an activity (e.g., inhibition of a target), means thatthe agent discriminates between potential target entities or states. Forexample, an agent binds “specifically” to its intended target (orotherwise specifically inhibits its target) if it preferentially bindsor otherwise inhibits the expression or activity of that target in thepresence of one or more alternate targets. Although the invention is notso limited, a specific and direct interaction can depend uponrecognition of a particular structural feature of the target (e.g., anepitope, a cleft, or a binding site). Specificity need not be absolute;the degree of specificity need only be enough to result in an effectivetreatment without unacceptable side effects. The specificity of an agentcan be evaluated by comparing the effect of the agent on an intendedtarget or state relative to its effect on a distinct target or state.The effects on the intended and distinct targets can each be determinedor the effect on the intended target can be determined and compared to areference standard developed at an earlier time (e.g., a referencespecific binding agent or a reference non-specific binding agent). Insome embodiments, the agent does not detectably bind the competingalternative target under conditions in which it detectably (and,preferably, significantly) binds its intended target and/or does notdetectably inhibit the expression or activity of the competing targetunder conditions in which it detectably (and, preferably, significantly)inhibits the expression or activity of its intended target. A compoundof the invention or a salt, solvate, stereoisomer, tautomer, or isotopicform thereof, may exhibit, with respect to its target(s), a higheron-rate, lower off-rate, increased affinity, decreased dissociation,and/or increased stability compared with the competing alternativetarget, and any of these parameters can be assessed in methods of theinvention.

The term “substantially” refers to the qualitative condition ofexhibiting a characteristic or property of interest to a total ornear-total extent or degree. One of ordinary skill in the art willunderstand that biological and chemical phenomena rarely, if ever, go tocompletion and/or proceed to completeness or achieve or avoid anabsolute result. The term “substantially” is therefore used herein tocapture the potential lack of completeness inherent in many biologicaland chemical phenomena. For example, a chemical reaction may becharacterized as substantially complete even though the yield is wellbelow 100%. Certain features may also be deemed “substantiallyidentical” when they are about the same and/or exhibit about the sameactivity. For example, two nearly identical compounds that produce aboutthe same effect on an event (e.g., cellular proliferation) may bedescribed as substantially similar. With regard to the purity of acompound or composition, “substantially pure” is defined below.

An individual (e.g., an individual subject or patient) who is“susceptible to” a disease (e.g., a cancer) has a greater than averagerisk for developing the disease. Such an individual may not display anysymptoms of the disease and may not have been diagnosed with the diseasebut is considered at risk due to, for example, exposure to conditionsassociated with development of the disease (e.g., exposure to acarcinogen). The risk of developing a disease can be population-based.

A “sign or symptom is reduced” when one or more objective signs orsubjective symptoms of a particular disease are reduced in magnitude(e.g., intensity, severity, etc.) and/or frequency. A delay in the onsetof a particular sign or symptom is one form of reducing the frequency ofthat sign or symptom. Reducing a sign or symptom can be achieved by,e.g., a “therapeutically active” compound.

The term “substantially pure,” when used to refer to a compounddescribed herein or a specified form thereof, means that a preparationof the compound or the specified form thereof is more than about 85%(w/w) compound or the specified form thereof (e.g., more than about 90%,95%, 97%, 98%, 99%, or 99.9% compound or a salt, solvate, stereoisomer,tautomer, or isomer).

A “tautomer” is an interchangeable form of a particular compoundstructure that varies by virtue of displaced hydrogen atoms andelectrons. Thus, two chemical structures may be in equilibrium throughthe movement of t electrons and an atom (usually H). For example, enolsand ketones are tautomers because they are rapidly interconverted bytreatment with either acid or base. Another example of tautomerism isthe aci- and nitro-forms of phenylnitromethane that are likewise formedby treatment with acid or base. Tautomeric forms can be used to optimizechemical reactivity and biological activity of a compound of interest.

A “therapeutic regimen” refers to a dosing regimen that, whenadministered across a relevant population, is correlated with a desiredtherapeutic outcome.

The term “treatment,” and linguistic variants thereof, such as“treat(s)” and “treating,” refer to any use of a pharmaceuticalcomposition or administration of a therapy that partially orsubstantially completely alleviates, ameliorates, relives, inhibits,reduces the severity of, and/or reduces the incidence of one or moresigns or symptoms of a particular disease (e.g., a proliferative diseasesuch as cancer). The subject being treated (or who has been identifiedas a candidate for treatment (e.g., a “newly diagnosed” patient) mayexhibit only early signs or symptoms of the disease or may exhibit oneor more established or advanced signs or symptoms of the disease.“Treatment” is distinguished from “prophylaxis” (defined below). In thatcase, the subject will not exhibit signs and/or symptoms of the diseaseand/or may be known to have one or more susceptibility factors that arestatistically correlated with increased risk of development of therelevant disease. However, once a patient exhibits signs or symptoms ofa disease and has been treated, treatment may be continued to delayprogression of the disease (e.g., in the event of a localized cancer,treatment may delay tumor progression (i.e., growth) or metastasis) orto delay or prevent recurrence (e.g., reappearance of a tumor).

The Applicant describes herein compounds of the invention havingstructural Formula (I):

or a pharmaceutically acceptable salt, solvate (e.g., hydrate),stereoisomer, tautomer, or isotopic form thereof. Within Formula (I), R¹is methyl or ethyl; R² is methyl or ethyl; R³ is 5-methylpiperidin-3-yl,5,5-dimethylpiperidin-3-yl, 6-methylpiperidin-3-yl, or6,6-dimethylpiperidin-3-yl; and R⁴ is —CF₃ or chloro. In someembodiments, in a compound of structural Formula (I), or a specifiedform thereof (e.g., a pharmaceutically acceptable salt, solvate,stereoisomer, or tautomer thereof), one or more atoms (e.g., one or morecarbon and/or hydrogen atoms within, e.g., a monocyclic or bicyclic ringstructure, R¹, R², R³, and/or R⁴) are replaced with an isotope of theoriginally present atom (e.g., an originally present ¹²C is replacedwith ¹³C or ¹⁴C and/or an originally present ¹H is replaced with ²H or³H). That is, the invention encompasses isotopic forms of a compound ofstructural Formula (I) as well as isotopic forms of a salt, solvate,stereoisomer, or tautomer thereof. As noted, a compound of structuralFormula (I) can be in the form of a solvate (e.g., a hydrate), and theinvention encompasses solvates (e.g., hydrates) of a compound ofstructural Formula (I) as well as solvates of a salt, stereoisomer,tautomer, or isotopic form of a compound of Formula (I). As noted, acompound of structural Formula (I) can be in the form of a salt, and theinvention encompasses salts of a compound of Formula (I) when thecompound is in another specified form (e.g., the invention encompasses asalt of a solvate, stereo-isomer, tautomer, or isotopic form of acompound of Formula (I)). In some embodiments, including those featuringthe specified forms just mentioned, the compound has structural Formula(Ia):

or is a pharmaceutically acceptable salt, solvate (e.g., hydrate),tautomer, isotopic, or other specified form thereof (e.g., apharmaceutically acceptable salt thereof (e.g., a salt of an isotopicform)). R¹, R², and R⁴ are as defined for structural Formula (I), and R³is

As indicated above with regard to Formula (I), any compound of Formula(Ia) or any salt, solvate, or tautomer thereof can be an isotopic form(e.g., one or more carbon and/or hydrogen atoms in a monocyclic orbicyclic ring structure, R¹, R², R³, and/or R⁴ is replaced by an isotopethereof (e.g., deuterium for ¹H)).

In some embodiments of a structural formula disclosed herein (e.g.,Formula (I) or (Ia)), each of R¹ and R² is, independently, methyl, —CD₃,ethyl, —CD₂CD₃, —CH₂CD₃, or —CH₂CD₃, where “D” represents deuterium.

In some embodiments, the compound of Formula (I) or Formula (Ia) is

In other embodiments, the invention features a pharmaceuticallyacceptable salt, solvate (e.g., hydrate), tautomer, or isotopic form ofany of the three foregoing compounds. In other embodiments, theinvention features another specified form of any of the three foregoingcompounds. For example, the invention encompasses a pharmaceuticallyacceptable salt of a solvate (e.g., hydrate), tautomer, or isotopic formof any of the three foregoing compounds.

In some embodiments, the compound is:

or a pharmaceutically acceptable salt, solvate (e.g., hydrate), ortautomer thereof (e.g., a pharmaceutically acceptable salt thereof), oran isotopic variant of the compound or any of the foregoing specifiedforms thereof. The isotopic variant can be as otherwise described above(e.g., one or more hydrogen atoms (e.g., in the substituent

is replaced by deuterium). In some embodiments of structural Formula (I)or Formula I(a), R³ is (5S)-5-methylpiperidin-3-yl

5,5-dimethylpiperidin-3-yl

(6S)-6-methylpiperidin-3-yl

6,6-dimethylpiperidin-3-yl

(5S)-5-trideuteromethylpiperidin-3-yl

5,5-di-trideuteromethylpiperidin-3-yl

(6S)-6-trideuteromethyl-piperidin-3-yl

or 6,6-di-trideuteromethylpiperidin-3-yl

In some embodiments of structural Formula (I) or Formula (Ia), R³ is(3S,5S)-5-methylpiperidin-3-yl

(3S)-5,5-dimethylpiperidin-3-yl

(3S,6S)-6-methylpiperidin-3-yl

(3S)-6,6-dimethylpiperidin-3-yl

(3S, 5S)-5-trideuteromethylpiperidin-3-yl

(3S)-5,5-di-trideuteromethylpiperidin-3-yl

(3S,6 S)-6-trideuteromethyl-piperidin-3-yl

or (3S)-6,6-di-trideuteromethylpiperidin-3-yl

Where R³ is as described above, R¹ can be methyl or ethyl; R² can bemethyl or ethyl; and R⁴ can be —CF₃ or chloro. For example, where R³ isas described above, R¹ can be methyl, R² can be methyl, and R⁴ can be—CF₃. It should also be noted that the stereochemical R/S designator forthe attachment position of R³ (e.g., the 3-position in the abovesubstituted piperidine examples), is based on the R³ group beingattached to the core of Formula (I) or (Ia), which gives the core an R/Spriority of “1” in the above examples.

In various, independent embodiments of structural Formula (I), (Ia), aspecies thereof or a specified form thereof: R¹ is methyl or ethyl; R²is methyl or ethyl; R¹ is methyl and R² is ethyl; R¹ and R² aresimultaneously methyl; or R¹ and R² are simultaneously ethyl. In variousembodiments, R³ is 5-methylpiperidin-3-yl (e.g., (3S,5S)-5-methylpiperidin-3-yl), 5,5-dimethylpiperidin-3-yl (e.g., (3S)-5,5-dimethylpiperidin-3-yl), 6-methylpiperidin-3-yl (e.g.,(3S,5S)-6-methylpiperidin-3-yl), or 6,6-dimethylpiperidin-3-yl (e.g.,(3S)-6,6,dimethylpiperidin-3-yl); R³ is (3S,5S)-5-methylpiperidin-3-yl;R³ is (3S)-5,5-dimethylpiperidin-3-yl; R³ is(3S,6S)-6-methylpiperidin-3-yl; or R³ is(3S)-6,6-dimethylpiperidin-3-yl. In more specific embodiments, R¹ ismethyl or ethyl, R² is methyl or ethyl, and R³ is 5-methylpiperidin-3-yl(e.g., (3S,5S)-5-methylpiperidin-3-yl); R¹ is methyl or ethyl, R² ismethyl or ethyl, and R³ is 5,5-dimethylpiperidin-3-yl (e.g.,(3S)-5,5-dimethylpiperidin-3-yl); R¹ is methyl or ethyl, R² is methyl orethyl, and R³ is 6-methylpiperidin-3-yl (e.g.,(3S,6S)-6-methylpiperidin-3-yl); or R¹ is methyl or ethyl, R² is methylor ethyl, and R³ is 6,6-dimethylpiperidin-3-yl (e.g.,(3S)-6,6-dimethylpiperidin-3-yl). In more specific embodiments, R¹ ismethyl, R² is ethyl and R³ is 5-methylpiperidin-3-yl (e.g.,(3S,5S)-5-methylpiperidin-3-yl); R¹ is methyl, R² is ethyl and R³ is5,5-dimethylpiperidin-3-yl (e.g., (3S)-5,5-dimethylpiperidin-3-yl); R¹is methyl, R² is ethyl and R³ is 6-methylpiperidin-3-yl (e.g., (3S,6S)-6-methylpiperidin-3-yl); or R¹ is methyl, R² is ethyl and R³ is6,6-dimethylpiperidin-3-yl (e.g., (3S)-6,6-dimethylpiperidin-3-yl). Inmore specific embodiments, R¹ and R² are simultaneously methyl and R³ is5-methylpiperidin-3-yl (e.g., (3S,5S)-5-methylpiperidin-3-yl); R¹ and R²are simultaneously methyl and R³ is 5,5-dimethylpiperidin-3-yl (e.g.,(3S)-5,5-dimethylpiperidin-3-yl); R¹ and R² are simultaneously methyland R³ is 6-methylpiperidin-3-yl (e.g., (3S,6S)-6-methylpiperidin-3-yl); or R¹ and R² are simultaneously methyland R³ is 6,6-dimethylpiperidin-3-yl (e.g.,(3S)-6,6-dimethylpiperidin-3-yl). In more specific embodiments, R¹ andR² are simultaneously ethyl and R³ is 5-methylpiperidin-3-yl (e.g.,(3S,5S)-5-methylpiperidin-3-yl); R¹ and R² are simultaneously ethyl andR³ is 5,5-dimethylpiperidin-3-yl (e.g.,(3S)-5,5-dimethylpiperidin-3-yl); R¹ and R² are simultaneously ethyl andR³ is 6-methylpiperidin-3-yl (e.g., (3S,6S)-6-methylpiperidin-3-yl); orR¹ and R² are simultaneously ethyl and R³ is 6,6-dimethylpiperidin-3-yl(e.g., (3S)-6,6-dimethylpiperidin-3-yl).

In some embodiments of structural Formula (I) or Formula (Ia), R⁴ is—CF₃. In more specific embodiments, R¹ is methyl or ethyl, R² is methylor ethyl, R³ is 5-methylpiperidin-3-yl (e.g.,(3S,5S)-5-methylpiperidin-3-yl) and R⁴ is —CF₃; R¹ is methyl or ethyl,R² is methyl or ethyl, R³ is 5,5-dimethylpiperidin-3-yl (e.g.,(3S)-5,5-dimethylpiperidin-3-yl), and and R⁴ is —CF₃; R¹ is methyl orethyl, R² is methyl or ethyl, R³ is 6-methylpiperidin-3-yl (e.g.,(3S,6S)-6-methylpiperidin-3-yl), and R⁴ is —CF₃; or R¹ is methyl orethyl, R² is methyl or ethyl, R³ is 6,6-dimethylpiperidin-3-yl (e.g.,(3S)-6,6-dimethylpiperidin-3-yl), and R⁴ is —CF₃. In more specificembodiments, R¹ is methyl, R² is ethyl, R³ is 5-methylpiperidin-3-yl(e.g., (3S,5S)-5-methylpiperidin-3-yl) and R⁴ is —CF₃; R¹ is methyl, R²is ethyl, R³ is 5,5-dimethylpiperidin-3-yl (e.g.,(3S)-5,5-dimethylpiperidin-3-yl) and R⁴ is —CF₃; R¹ is methyl, R² isethyl, R³ is 6-methylpiperidin-3-yl (e.g.,(3S,6S)-6-methylpiperidin-3-yl) and R⁴ is —CF₃; or R¹ is methyl, R² isethyl, R³ is 6,6-dimethylpiperidin-3-yl (e.g.,(3S)-6,6-dimethylpiperidin-3-yl), and R⁴ is —CF₃. In more specificembodiments, R¹ and R² are simultaneously methyl, R³ is5-methylpiperidin-3-yl (e.g., (3,S,5S)-5-methylpiperidin-3-yl), and R⁴is —CF₃; R¹ and R² are simultaneously methyl, R³ is5,5-dimethylpiperidin-3-yl (e.g., (3S)-5,5-dimethylpiperidin-3-yl), andR⁴ is —CF₃; R¹ and R² are simultaneously methyl, R³ is6-methylpiperidin-3-yl (e.g., (3S,6S)-6-methylpiperidin-3-yl), and R⁴ is—CF₃; or R¹ and R² are simultaneously methyl, R³ is6,6-dimethylpiperidin-3-yl (e.g., (3S)-6,6-dimethylpiperidin-3-yl), andR⁴ is —CF₃. In more specific embodiments, R¹ and R² are simultaneouslyethyl, R³ is 5-methylpiperidin-3-yl (e.g.,(3S,5S)-5-methylpiperidin-3-yl), and R⁴ is —CF₃; R¹ and R² aresimultaneously ethyl, R³ is 5,5-dimethylpiperidin-3-yl (e.g.,(3S)-5,5-dimethylpiperidin-3-yl), and R⁴ is —CF₃; R¹ and R² aresimultaneously ethyl, R³ is 6-methylpiperidin-3-yl (e.g.,(3S,6S)-6-methylpiperidin-3-yl), and R⁴ is —CF₃; or R¹ and R² aresimultaneously ethyl, R³ is 6,6-dimethylpiperidin-3-yl (e.g.,(3S)-6,6-dimethylpiperidin-3-yl), and R⁴ is —CF₃.

In some embodiments of structural Formula (I) or Formula (Ia), R⁴ ischloro. In more specific embodiments, R¹ is methyl or ethyl, R² ismethyl or ethyl, R³ is 5-methylpiperidin-3-yl (e.g.,(3S,5S)-5-methylpiperidin-3-yl) and R⁴ is chloro; R¹ is methyl or ethyl,R² is methyl or ethyl, R³ is 5,5-dimethylpiperidin-3-yl (e.g.,(3S)-5,5-dimethylpiperidin-3-yl), and and R⁴ is chloro; R¹ is methyl orethyl, R² is methyl or ethyl, R³ is 6-methylpiperidin-3-yl (e.g.,(3S,6S)-6-methylpiperidin-3-yl), and R⁴ is chloro; or R¹ is methyl orethyl, R² is methyl or ethyl, R³ is 6,6-dimethylpiperidin-3-yl (e.g.,(3S)-6,6-dimethylpiperidin-3-yl), and R⁴ is chloro. In more specificembodiments, R¹ is methyl, R² is ethyl, R³ is 5-methylpiperidin-3-yl(e.g., (3S,5S)-5-methylpiperidin-3-yl) and R⁴ is chloro; R¹ is methyl,R² is ethyl, R³ is 5,5-dimethylpiperidin-3-yl (e.g.,(3S)-5,5-dimethylpiperidin-3-yl) and R⁴ is chloro; R¹ is methyl, R² isethyl, R³ is 6-methylpiperidin-3-yl (e.g.,(3S,6S)-6-methylpiperidin-3-yl) and R⁴ is chloro; or R¹ is methyl, R² isethyl, R³ is 6,6-dimethylpiperidin-3-yl (e.g.,(3S)-6,6-dimethylpiperidin-3-yl), and R⁴ is chloro. In more specificembodiments, R¹ and R² are simultaneously methyl, R³ is5-methylpiperidin-3-yl (e.g., (3S,5S)-5-methylpiperidin-3-yl), and R⁴ ischloro; R¹ and R² are simultaneously methyl, R³ is5,5-dimethylpiperidin-3-yl (e.g., (3S)-5,5-dimethylpiperidin-3-yl), andR⁴ is chloro; R¹ and R² are simultaneously methyl, R³ is6-methylpiperidin-3-yl (e.g., (3S,6S)-6-methylpiperidin-3-yl), and R⁴ ischloro; or R¹ and R² are simultaneously methyl, R³ is6,6-dimethylpiperidin-3-yl (e.g., (3S)-6,6-dimethylpiperidin-3-yl), andR⁴ is chloro. In more specific embodiments, R¹ and R² are simultaneouslyethyl, R³ is 5-methylpiperidin (e.g., (3S,5S)-5-methylpiperidin-3-yl),and R⁴ is chloro; R¹ and R² are simultaneously ethyl, R³ is5,5-dimethylpiperidin-3-yl (e.g., (3S)-5,5-dimethylpiperidin-3-yl), andR⁴ is chloro; R¹ and R² are simultaneously ethyl, R³ is6-methylpiperidin-3-yl (e.g., (3S,6S)-6-methylpiperidin-3-yl), and R⁴ ischloro; or R¹ and R² are simultaneously ethyl, R³ is6,6-dimethylpiperidin-3-yl (e.g., (3S)-6.6-dimethylpiperidin-3-yl), andR⁴ is chloro.

Pharmaceutically acceptable salts of a compound described herein or asolvate, stereoisomer, tautomer, or isotopic form of the salts (or anyother specified form described herein), include those derived fromsuitable inorganic and organic acids and bases. That is, the inventionencompasses salt forms of a compound of structural Formula (I), I(a) orspecies thereof as well as salt forms of a solvate, stereoisomer,tautomer, or isotopic form thereof. Examples of pharmaceuticallyacceptable, acid addition salts are salts of an amino group formed withinorganic acids such as hydrochloric acid, hydrobromic acid, phosphoricacid, sulfuric acid and perchloric acid or with organic acids such asacetic acid, oxalic acid, maleic acid, tartaric acid, citric acid,succinic acid or malonic acid or by using other methods known in theart, such as ion exchange. Other pharmaceutically acceptable saltsinclude adipate, alginate, ascorbate, aspartate, benzenesulfonate,benzoate, besylate, bisulfate, borate, butyrate, camphorate,camphorsulfonate, citrate, cyclopentane-propionate, digluconate,dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate,glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate,hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate,lauryl sulfate, malate, maleate, malonate, methanesulfonate,2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate,pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate,propionate, stearate, succinate, sulfate, tartrate, thiocyanate,p-toluenesulfonate, undecanoate, and valerate salts.

The salt of any compound described herein can also be derived fromappropriate bases including alkali metal, alkaline earth metal, ammoniumand N⁺(C₁₋₄alkyl)₄ salts. Representative alkali or alkaline earth metalsalts include sodium, lithium, potassium, calcium, and magnesium. Otherpharmaceutically acceptable salts include, when appropriate, ammonium,quaternary ammonium, and amine cations formed using counterions such ashalide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkylsulfonate and aryl sulfonate.

A compound of the present invention, or a specified form as describedherein (e.g., a pharmaceutically acceptable salt, solvate, stereoisomer,tautomer, or isotropic form), may have one or more of the followingproperties: (1) at least or about 25-fold (e.g., at least or about50-fold, 100-fold, 200-fold, 300-fold, or 400-fold) greater specificityfor CDK7 than for each of CDK2, CDK9 and CDK12 in an enzymatic assay interms of K_(i); (2) at least or about 200-fold (e.g., at least or about300-fold, 400-fold, or 500-fold) greater specificity for CDK7 than foreach of CDK2, CDK9 and CDK12 in an enzymatic assay in terms of IC₅₀; (3)less than 150 pM (e.g., less than 120 pM, 110 pM, or 100 pM) K_(d)binding to a CDK7/cyclin H complex as measured by surface plasmonresonance (SPR); and (4) an EC₅₀ of less than 10 nM (e.g., less than 5nM, 4 nM, 3 nM, 2 nM or 1 nM) in an anti-proliferation assay using HCC70cells. These properties render a compound or a specified form thereofparticularly useful in therapies that require strong and specificinhibition of CDK7 without concomitant inhibition of other CDKs,particularly CDK2, CDK9 and CDK12.

Pharmaceutical Compositions and Kits:

The present invention provides pharmaceutical compositions that includea compound of Formula (I), (Ia), a species thereof, or a specified formas described herein (e.g., a pharmaceutically acceptable salt, solvate(e.g., hydrate), stereoisomer, tautomer, or isotopic form thereof) and,optionally, a pharmaceutically acceptable carrier. In certainembodiments, the pharmaceutical composition includes: a compound ofFormula (I) or (Ia), or a species thereof, or a pharmaceuticallyacceptable salt thereof; a compound of Formula (I) or (Ia), or a speciesthereof, in the form of a solvate (e.g., a hydrate); a compound ofFormula (I) or (Ia), or a species thereof, in a stereoisomeric form or amixture thereof (e.g., where the stereoisomer is an enantiomer or aracemic mixture thereof); a compound of Formula (I) or (Ia), or aspecies thereof, in the form of a tautomer; or any of the foregoing inan isotopic form. As noted, a pharmaceutical composition can include oneor more pharmaceutically acceptable carriers, and the activeagent/ingredient (i.e., compound, regardless of form) can be providedtherein in an effective amount (e.g., a therapeutically effective amountor a prophylactically effective amount). In case of any doubt, any ofthe specified forms of a compound of Formula (I), (Ia), or a speciesthereof can be included in a pharmaceutical composition of theinvention.

Pharmaceutical compositions of the invention can be prepared by relevantmethods known in the art of pharmacology. In general, such preparatorymethods include the steps of bringing a compound described herein,including compounds of Formula (I), (Ia), a species thereof, or aspecified form thereof (e.g., a pharmaceutically acceptable salt,solvate, stereoisomer, tautomer, or isotopic form thereof) intoassociation with a carrier and/or one or more other active ingredients(e.g., one or more of the second agents described herein) and/oraccessory ingredients, and then, if necessary and/or desirable, shapingand/or packaging the product into a desired single-dose or multi-doseunit (e.g., for oral dosing). The accessory ingredient may improve thebioavailability of a compound of Formula (I), (Ia), a species thereof,or a specified form thereof, may reduce and/or modify its metabolism,may inhibit its excretion, and/or may modify its distribution within thebody (e.g., by targeting a diseased tissue (e.g., a tumor). Thepharmaceutical compositions can be packaged in various ways, includingin bulk containers and as single unit doses (containing, e.g., discrete,predetermined amounts of the active agent) or a plurality thereof, andany such packaged or divided dosage forms are within the scope of thepresent invention. The amount of the active ingredient can be equal tothe amount constituting a unit dosage or a convenient fraction of adosage such as, for example, one-half or one-third of a dose.

Relative amounts of the active agent/ingredient, the pharmaceuticallyacceptable carrier(s), and/or any additional ingredients in apharmaceutical composition of the invention can vary, depending upon theidentity, size, and/or condition of the subject treated and furtherdepending upon the route by which the composition is to be administeredand the disease to be treated. By way of example, the composition maycomprise between about 0.1% and 99.9% (w/w or w/v) of an activeagent/ingredient.

Pharmaceutically acceptable carriers useful in the manufacture of thepharmaceutical compositions described herein are well known in the artof pharmaceutical formulation and include inert diluents, dispersingand/or granulating agents, surface active agents and/or emulsifiers,disintegrating agents, binding agents, preservatives, buffering agents,lubricating agents, and/or oils. Pharmaceutically acceptable carriersuseful in the manufacture of the pharmaceutical compositions describedherein include, but are not limited to, ion exchangers, alumina,aluminum stearate, lecithin, serum proteins, such as human serumalbumin, buffer substances such as phosphates, glycine, sorbic acid,potassium sorbate, partial glyceride mixtures of saturated vegetablefatty acids, water, salts or electrolytes, such as protamine sulfate,disodium hydrogen phosphate, potassium hydrogen phosphate, sodiumchloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodiumcarboxymethylcellulose, polyacrylates, waxes,polyethylene-polyoxypropylene-block polymers, polyethylene glycol andwool fat.

Pharmaceutical compositions of the present invention may be administeredorally and oral formulations are within the scope of the presentinvention. Such orally acceptable dosage forms may be solid (e.g., acapsule, tablet, sachet, powder, granule, and orally dispersible film)or liquid (e.g., an ampoule, semi-solid, syrup, suspension, or solution(e.g., aqueous suspensions or dispersions and solutions). In the case oftablets, carriers commonly used include lactose and corn starch.Lubricating agents, such as magnesium stearate, can also be included. Inthe case of capsules, useful diluents include lactose and driedcornstarch. When aqueous suspensions are formulated, the activeagent/ingredient can be combined with emulsifying and suspending agents.In any oral formulation, sweetening, flavoring or coloring agents mayalso be added. In any of the various embodiments described herein, anoral formulation can be formulated for immediate release orsustained/delayed release and may be coated or uncoated. A providedcomposition can also be in a micro-encapsulated form.

Compositions suitable for buccal or sublingual administration includetablets, lozenges and pastilles. Formulations can also be prepared forsubcutaneous, intravenous, intramuscular, intraocular, intravitreal,intra-articular, intra-synovial, intrasternal, intrathecal,intrahepatic, intraperitoneal intralesional and by intracranialinjection or infusion techniques. Preferably, the compositions areadministered orally, subcutaneously, intraperitoneally or intravenously.Sterile injectable forms of the compositions of this invention may beaqueous or oleaginous suspension. These suspensions may be formulatedaccording to techniques known in the art using suitable dispersing orwetting agents and suspending agents. The sterile injectable preparationmay also be a sterile injectable solution or suspension in a non-toxicparenterally acceptable diluent or solvent, for example as a solution in1,3-butanediol. Among the acceptable vehicles and solvents that may beemployed are water, Ringer's solution and isotonic sodium chloridesolution. In addition, sterile, fixed oils are conventionally employedas a solvent or suspending medium.

Although the descriptions of pharmaceutical compositions provided hereinare principally directed to pharmaceutical compositions which aresuitable for administration to humans, it will be understood by one ofordinary skill in the art that such compositions are generally suitablefor administration to animals of all sorts. Modification ofpharmaceutical compositions suitable for administration to humans inorder to render the compositions suitable for administration to variousanimals is well understood, and the ordinarily skilled veterinarypharmacologist can design and/or perform such modification.

Compounds described herein are typically formulated in dosage unit form,e.g., single unit dosage form, for ease of administration and uniformityof dosage. The specific therapeutically or prophylactically effectivedose level for any particular subject or organism will depend upon avariety of factors including the disease being treated and the severityof the disorder; the activity of the specific active ingredientemployed; the specific composition employed; the age, body weight,general health, sex and diet of the subject; the time of administration,route of administration, and rate of excretion of the specific activeingredient employed; the duration of the treatment; drugs used incombination or coincidental with the specific active ingredientemployed; and like factors well known in the medical arts.

The exact amount of a compound required to achieve an effective amountcan vary from subject to subject, depending, for example, on species,age, and general condition of a subject, severity of the side effects,disease to be treated, identity of the particular compound(s) to beadministered, mode of administration, and the like. The desired dosagecan be delivered three times a day, two times a day, once a day, everyother day, every third day, every week, every two weeks, every threeweeks, or every four weeks. In certain embodiments, the desired dosagecan be delivered using multiple administrations (e.g., two, three, four,five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen,or more administrations).

In certain embodiments, an effective amount of a compound foradministration one or more times a day (e.g., once) to a 70 kg adulthuman may comprise about 1-100 mg, about 1-50 mg, about 1-35 mg (e.g.,about 1-5, 1-10, 1-15, 1-20, 1-25, or 1-30 mg), about 2-20 mg, about3-15 mg or about 10-30 mg (e.g., 10-20 or 10-25 mg). Here, and whereverranges are referenced, the end points are included. The dosages providedin this disclosure can be scaled for patients of differing weights orbody surface and may be expressed per m² of the patient's body surface.

In certain embodiments, compositions of the invention may beadministered once per day. The dosage of a compound of Formula I or asubgenus or species thereof or a specified form thereof (e.g., a saltthereof) can be about 1-100 mg, about 1-50 mg, about 1-25 mg, about 2-20mg, about 5-15 mg, about 10-15 mg, or about 13-14 mg.

In certain embodiments, a composition of the invention may beadministered twice per day. In some embodiments, the dosage of acompound of Formula I or a subgenus or species thereof for eachadministration is about 0.5 mg to about 50 mg, about 0.5 mg to about 25mg, about 0.5 mg to about 1 mg, about 1 mg to about 10 mg, about 1 mg toabout 5 mg, about 3 mg to about 5 mg, or about 4 mg to about 5 mg.

Dose ranges as described herein provide guidance for the administrationof provided pharmaceutical compositions to an adult. The amount to beadministered to, for example, a child or an adolescent can be determinedby one of ordinary skill in the art and can be lower or the same as thatadministered to an adult.

A compound or other composition described herein (e.g., a pharmaceuticalcomposition) can be administered in a combination therapy (e.g., asdefined and further described herein). The additional/second agentemployed in a combination therapy (and, where present, the third agent)is most likely to achieve a desired effect for the same disorder (e.g.,the same cancer), however it may achieve different effects that aid thepatient. Accordingly, the invention features pharmaceutical compositionscontaining a compound of Formula (I), (Ia), a species thereof, or aspecified form thereof (e.g., a pharmaceutically acceptable salt), in atherapeutically effect amount; one or more additional agents, includingany of the additional/second agents described herein; and apharmaceutically acceptable carrier. The second/additional agent can beselected from a Bcl-2 inhibitor such as venetoclax, a PARP inhibitorsuch as olaparib or niraparib, a platinum-based anti-cancer agent suchas carboplatin, cisplatin, or oxaliplatin, a taxane such as docetaxel orpaclitaxel (or paclitaxel protein-bound (available as Abraxane®)), aCDK4/6 inhibitor such as palbociclib, ribociclib, abemaciclib, ortrilaciclib, a selective estrogen receptor modulator (SERM) such astamoxifen (available under the brand names Nolvadex™ and Soltamox™),raloxifene (available under the brand name Evista™), and toremifene(available as Fareston™), and a selective estrogen receptor degradersuch as fulvestrant (available as Faslodex™), each in a therapeuticallyeffective amount.

Methods of Treatment and Use: A compound of Formula (I), (Ia), a speciesthereof, or a specified form thereof (e.g., a salt, solvate,stereoisomer, tautomer, or isotopic form thereof) and other compositionsdescribed herein (e.g., pharmaceutical compositions, including thoseformulated in unit dosage forms) have a variety of uses, including inresearch and/or in clinical settings (e.g., in prophylactic ortherapeutic methods). In some embodiments, the compounds and othercompositions described herein (e.g., pharmaceutical compositions andkits) are configured for and used in preventing or treating aproliferative disease (e.g., a cancer, benign neoplasm, or pathologicangiogenesis) in a patient in need thereof. The cancer can be selectedfrom among those disclosed herein (e.g., a blood cancer, a cancercharacterized by the presence of a solid tumor in the breast, GI tract(e.g., a CRC), lung (e.g., NSCLC), pancreas, or prostate, or Ewing'ssarcoma). In any embodiment of the methods of the invention, one mayobtain information by carrying out or procuring the results of teststhat characterize the type or grade of cancer afflicting the patient.For example, the methods and uses described herein can be applied to apatient who has been determined to have a “high grade” cancer (e.g.,high grade serous ovarian cancer); determined to have tumor cells thatexhibit a certain phenotype (e.g., to have breast cancer cells that areestrogen receptor-positive (ER+) or “triple negative”); and/ordetermined to have become resistant to treatment with a previouslyadministered therapeutic agent (e.g., a chemotherapeutic agent such asanother CDK inhibitor (e.g., palbociclib) or a receptor-degrading agent(e.g., fulvestrant)). The methods and uses described herein can includea step to make the determinations just mentioned; a step of determiningwhether a patient has a high-grade cancer, tumor cells of a specifiedphenotype, or has developed resistance to a previously administeredtherapeutic agent. The methods of treatment require administering to apatient in need thereof a therapeutically effective amount of a compounddescribed herein (e.g., a compound having the structure depicted inFormula I or a subgenus or species thereof, in a form specified herein(e.g., as a salt or mixture of enantiomers) in a pharmaceuticallyacceptable composition to reduce a sign or symptom of the disease).

Each therapeutic or prophylactic method that employs a compound ofFormula (I), (Ia), a species thereof, or a specified form thereof, orother composition described herein (e.g., a pharmaceutical composition)and involves administration of the compound or composition to a patientmay also be expressed in terms of “use” and vice versa. For example, theinvention encompasses the use of a compound described herein, in anyspecified form, or the use of a composition described herein for: thetreatment of a disease described herein (e.g., a proliferative diseasesuch as cancer (e.g., any blood/hematological cancer described herein ora solid tumor in, e.g., the breast, GI tract (e.g., CRC), lung (e.g.,NSCLC), pancreas, or prostate)); the treatment of an inflammatorydisease, autoimmune disease, or autoinflammatory disease, including anyone or more of the specific diseases set out herein within thedefinitions of these types of diseases); the preparation a medicamentfor treating a disease described herein (e.g., a proliferative diseasesuch as cancer, or an inflammatory, autoimmune, or autoinflammatorydisease).

The methods of the invention that concern treating a disease describedherein (e.g., a proliferative disease such as cancer (e.g., a bloodcancer, breast cancer, GI tract cancer (e.g., a CRC), lung cancer (e.g.,NSCLC), pancreatic cancer, prostate cancer, or Ewing's sarcoma) mayspecifically exclude any one or more of the types of diseases (e.g., anyone or more of the types of cancer) described herein. For example, theinvention features methods of treating cancer by administering acompound of Formula (I), (Ia), a species thereof, or a specified formthereof) with the proviso that the cancer is not a breast cancer; withthe proviso that the cancer is not a breast cancer or a blood cancer(e.g., leukemia); with the proviso that the cancer is not a breastcancer, a blood cancer (e.g., leukemia), or an ovarian cancer; and soforth, with exclusions selected from any of the diseases/cancer typeslisted herein and with the same notion of variable exclusion from listsof elements relevant to other aspects and embodiments of the invention(e.g., chemical substituents of a compound described herein orcomponents of kits and pharmaceutical compositions). Thus, whereelements are presented as lists (e.g., in Markush group format), everypossible subgroup of the elements is also disclosed, and any element(s)can be removed from the group.

In various embodiments, the subject being treated is: a mammal; a human;a domesticated or companion animal, such as a dog, cat, cow, pig, horse,sheep, or goat; a zoo animal; or a research animal such as a rodent,dog, non-human primate (e.g. a cynomolgus monkey or rhesus monkey), ornon-human transgenic animal such as a transgenic mouse or transgenicpig. Where the patient is a human, the human may be a male, female, ortransgendered person of any age group (e.g., a pediatric patient (e.g.,an infant, child, or adolescent) or an adult patient (e.g., a youngadult, middle-aged adult, or senior adult)). Similarly, where thepatient is a non-human animal (e.g., a mammal), it may be a male orfemale of any age or developmental stage. Birds, particularly thosehaving commercial value, are also suitable patients.

The proliferative disease to be treated or prevented using the compoundsof Formula I or a subgenus or species thereof in any specified form canbe associated with aberrant activity of CDK7. Aberrant activity of CDK7may be an elevated and/or an inappropriate (e.g., abnormal) activity ofCDK7. In certain embodiments, CDK7 is not overexpressed, and theactivity of CDK7 is elevated and/or inappropriate (e.g., the CDK7 is amutant CDK7 with increased activity, additional unwanted activity,resistance to native activity modulation, resistance to degradation,etc., as compared to wild-type CDK7). In certain other embodiments, CDK7is overexpressed (at the mRNA and/or protein level), and the activity ofCDK7 is elevated and/or inappropriate. The compounds of Formula (I),(Ia), or of a subgenus or species thereof, and pharmaceuticallyacceptable salts, solvates, stereoisomers, tautomers, isotopic forms,and compositions as described herein (i.e., compositions containing oneor more of the foregoing), may inhibit the activity of CDK7 and beuseful in treating and/or preventing proliferative diseases, includingthose described herein.

A proliferative disease may also be associated with inhibition ofapoptosis of a cell in a biological sample or subject. Although theinvention is not limited by any underlying mechanism of action,inhibiting the activity of CDK7 is expected to cause cytotoxicity viainduction of apoptosis. The compositions of the invention may induceapoptosis, and therefore, be useful in treating and/or preventingproliferative diseases, particularly proliferative diseases in whichCDK7 is overexpressed or overly active.

As noted, in certain embodiments, the proliferative disease to betreated or prevented using a composition of the invention is cancer. Alltypes of cancers disclosed herein or known in the art are contemplatedas being within the scope of the invention, but particularly those thatare known to be associated with CDK7 activity (e.g., overactivity,overexpression, or misexpression).

In certain embodiments, the proliferative disease is a blood cancer,which may also be referred to as a hematopoietic or hematological canceror malignancy. More specifically and in various embodiments, the bloodcancer can be a leukemia such as acute lymphocytic leukemia (ALL; e.g.,B cell ALL or T cell ALL), acute myelocytic leukemia (AML; e.g., B cellAML or T cell AML), chronic myelocytic leukemia (CML; e.g., B cell CMLor T cell CML), chronic lymphocytic leukemia (CLL; e.g., B cell CLL(e.g., hairy cell leukemia) or T cell CLL), chronic neutrophilicleukemia (CNL), or chronic myelomonocytic leukemia (CMML). The bloodcancer can also be a lymphoma such as Hodgkin lymphoma (HL; e.g., B cellHL or T cell HL), non-Hodgkin lymphoma (NHL, which can be deemedaggressive; e.g., B cell NHL or T cell NHL), follicular lymphoma (FL),chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL),mantle cell lymphoma (MCL), a marginal zone lymphoma (MZL), such as a Bcell lymphoma (e.g., splenic marginal zone B cell lymphoma), primarymediastinal B cell lymphoma (e.g., splenic marginal zone B celllymphoma), primary mediastinal B cell lymphoma, Burkitt lymphoma (BL),lymphoplasmacytic lymphoma (i.e., Waldenstrom's macroglobulinemia),immunoblastic large cell lymphoma, precursor B lymphoblastic lymphoma,or primary central nervous system (CNS) lymphoma. The B cell NHL can bediffuse large cell lymphoma (DLCL; e.g., diffuse large B cell lymphoma(DLBCL; e.g., germinal center B cell-like (GCB) DLBCL or activatedB-cell like (ABC) DLBCL)), and the T cell NHL can be precursor Tlymphoblastic lymphoma or a peripheral T cell lymphoma (PTCL). In turn,the PTCL can be a cutaneous T cell lymphoma (CTCL) such as mycosisfungoides or Sezary syndrome, angioimmunoblastic T cell lymphoma,extranodal natural killer T cell lymphoma, enteropathy type T celllymphoma, subcutaneous anniculitis-like T cell lymphoma, or anaplasticlarge cell lymphoma. While the invention is not limited to treating orpreventing blood cancers having any particular cause or presentation,stem cells within the bone marrow may proliferate, thereby becoming adominant cell type within the bone marrow and a target for a compounddescribed herein. Leukemic cells can accumulate in the blood andinfiltrate organs such as the lymph nodes, spleen, liver, and kidney. Insome embodiments, a compound of the present disclosure or a specifiedform thereof is useful in the treatment or prevention of a leukemia orlymphoma.

In other embodiments, the proliferative disease is characterized by asolid tumor considered to be either of its primary location ormetastatic. For example, in various embodiments, the cancer or tumortreated or prevented as described herein is an acoustic neuroma;adenocarcinoma; adrenal gland cancer; anal cancer; angiosarcoma (e.g.,lymphangiosarcoma, lymphangio-endotheliosarcoma, hemangiosarcoma);appendix cancer; benign monoclonal gammopathy (also known as monoclonalgammopathy of unknown significance (MGUS); biliary cancer (e.g.,cholangiocarcinoma); bladder cancer; breast cancer (e.g., adenocarcinomaof the breast, papillary carcinoma of the breast, mammary cancer,medullary carcinoma of the breast; any of which may be present insubjects having a particular profile, such as an HR+(ER+ or PR+), HER2+,HR− (having neither estrogen nor progesterone receptors), a triplenegative breast cancer (TNBC; ER−/PR−/HER2−), or a triple-positivebreast cancer (ER+/PR+/HER2+); a brain cancer (e.g., meningioma,glioblastoma, glioma (e.g., astrocytoma, oligodendroglioma),medulloblastoma); bronchus cancer; carcinoid tumor, which may be benign;cervical cancer (e.g., cervical adenocarcinoma); choriocarcinoma;chordoma; craniopharyngioma; a cancer present in the large intestine,such as colorectal cancer (CRC, e.g., colon cancer, rectal cancer, orcolorectal adenocarcinoma); connective tissue cancer; epithelialcarcinoma; ependymoma; endothelio-sarcoma (e.g., Kaposi's sarcoma ormultiple idiopathic hemorrhagic sarcoma); endometrial cancer (e.g.,uterine cancer, uterine sarcoma); esophageal cancer (e.g.,adenocarcinoma of the esophagus, Barrett's adenocarcinoma); Ewing'ssarcoma (or other pediatric sarcoma, such as embryonal rhabdomyosarcomaor alveolar rhabdomyosarcoma); eye cancer (e.g., intraocular melanoma,retinoblastoma); familiar hypereosinophilia; gallbladder cancer; gastriccancer (e.g., stomach adenocarcinoma); gastrointestinal stromal tumor(GIST); germ cell cancer; head and neck cancer (e.g., head and necksquamous cell carcinoma, oral cancer (e.g., oral squamous cellcarcinoma), throat cancer (e.g., laryngeal cancer, pharyngeal cancer,nasopharyngeal cancer, oropharyngeal cancer)); hypopharynx cancer;inflammatory myofibroblastic tumors; immunocytic amyloidosis; kidneycancer (e.g., nephroblastoma a.k.a. Wilms' tumor, renal cell carcinoma);liver cancer (e.g., hepatocellular cancer (HCC), malignant hepatoma);lung cancer (e.g., bronchogenic carcinoma, small cell lung cancer(SCLC), non-small cell lung cancer (NSCLC), adenocarcinoma, squamouscell carcinoma, or large cell carcinoma of the lung); leiomyosarcoma(LMS); mastocytosis (e.g., systemic mastocytosis); mouth cancer; musclecancer; myelodys-plastic syndrome (MDS); mesothelioma;myeloproliferative disorder (MPD) (e.g., polycythemia vera (PV),essential thrombocytosis (ET), agnogenic myeloid metaplasia (AMM) a.k.a.myelofibrosis (MF), chronic idiopathic myelofibrosis, hypereosinophilicsyndrome (HES)); neuroblastoma; neurofibroma (e.g., neurofibromatosis(NF) type 1 or type 2, schwannomatosis); neuroendocrine cancer (e.g.,gastroenteropancreatic neuroendocrine tumor (GEP-NET), carcinoid tumor);osteosarcoma (e.g., bone cancer); ovarian cancer (e.g.,cystadenocarcinoma, ovarian embryonal carcinoma, ovarian adenocarcinoma,HGSOC, LGSOC, epithelial ovarian cancer (e.g., ovarian clear cellcarcinoma or mucinous carcinoa), sex cord stromal tumors (granulosacell), and endometroid tumors); papillary adenocarcinoma; pancreaticcancer (whether an exocrine tumor (e.g., pancreatic adenocarcinoma,pancreatic ductal adenocarcinoma (PDAC)), intraductal papillary mucinousneoplasm (IPMN), or a neuroendocrine tumor (e.g., PNETs or islet celltumors); penile cancer (e.g., Paget's disease of the penis and scrotum);pinealoma; primary peritoneal cancer, primitive neuroectodermal tumor(PNT); plasma cell neoplasia; paraneoplastic syndromes; prostate cancer,which may be castration-resistant (e.g., prostate adenocarcinoma);rhabdomyosarcoma; salivary gland cancer; skin cancer (e.g., squamouscell carcinoma (SCC), keratoacanthoma (KA), melanoma, basal cellcarcinoma (BCC)); small bowel or small intestine cancer; soft tissuesarcoma (e.g., malignant fibrous histiocytoma (MFH), liposarcoma,malignant peripheral nerve sheath tumor (MPNST), chondrosarcoma,fibrosarcoma, myxosarcoma); sebaceous gland carcinoma; sweat glandcarcinoma; synovioma; testicular cancer (e.g., seminoma, testicularembryonal carcinoma); thyroid cancer (e.g., papillary carcinoma of thethyroid, papillary thyroid carcinoma (PTC), medullary thyroid cancer);urethral cancer; vaginal cancer; and vulvar cancer (e.g., Paget'sdisease of the vulva). We use the term “gastrointestinal (GI) tractcancer” to refer to a cancer present anywhere in the GI tract, includingcancers of the mouth, throat, esophagus, stomach, large or smallintestine, rectum, and anus. In some embodiments, the proliferativedisease is associated with pathologic angiogenesis, and the methods ofthe invention and uses of a compound described herein (or any specifiedform thereof) encompass inhibiting pathologic angiogenesis in thecontext of cancer treatment (e.g., of a blood cancer or solid tumor). Asnoted above, the cancer can be a neuroendocrine cancer, and such tumorscan be treated as described herein regardless of the organ in which theypresent.

In certain embodiments, the proliferative disease is an inflammatorydisease. All types of inflammatory diseases disclosed herein (see thedefinition above) or known in the art are contemplated as being withinthe scope of the invention. In certain embodiments, the inflammatorydisease is rheumatoid arthritis. In some embodiments, the proliferativedisease is an autoinflammatory disease. All types of autoinflammatorydiseases disclosed herein (see the definition above) or known in the artare contemplated as being within the scope of the invention. In someembodiments, the disease is an autoimmune disease (see the definition ofautoimmune disease above). All types of autoimmune diseases disclosedherein or known in the art are contemplated as being within the scope ofthe invention.

The therapeutic or prophylactic methods and “uses” described herein caninclude a step of administering one or more additional therapeuticallyactive agents (i.e., a “second” agent that is distinct from a compoundor other composition of the invention (e.g., a specified form of acompound described herein)) in combination with a composition of theinvention (e.g., a compound of Formula (I), (Ia), a species thereof, ora pharmaceutically acceptable salt, solvate, stereoisomer, tautomer, orisotopic form thereof, or a composition containing such a compound or aspecified form thereof (e.g., a pharmaceutically acceptable saltthereof, optionally in an isomeric form). We may refer to such methodsand uses as “combination therapies,” and we reiterate that any compounddescribed herein or any specified form thereof can be the “first”therapeutically active agent administered or in use in a combinationtherapy; the designations “first” and “second” provide a convenient wayto refer to two distinct agents without limiting the order or manner inwhich the first and second agents are administered. Thus, a patient mayreceive one or more of the second agents described herein prior toreceiving a compound of the invention. In fact, and as noted, a patientmay have a cancer that has become refractory to the second agent priorto administration of a compound of the invention. For example, acompound or pharmaceutical composition of the invention can be used oradministered to treat a patient who has become or is at risk of becomingresistant to treatment with a CDK4/6 inhibitor when used alone or incombination with one or more of an aromatase inhibitor, a selectiveestrogen receptor modulator or a selective estrogen receptor degrader.

Second agents include, but are not limited to, anti-proliferativeagents, anti-cancer agents, anti-diabetic agents, anti-inflammatoryagents, immunosuppressant agents, and pain-relieving agents. The secondagents may, but do not necessarily, synergistically augment inhibitionof CDK7 induced by the compounds or compositions of this invention(i.e., the “first” agent) in the biological sample or subject. Thecombination of the first and second agent(s) may be useful in treatingproliferative diseases resistant to a treatment using the secondagent(s) without the first agent(s). In this event, and as noted above,a compound of the invention or a specified form thereof, or acomposition of the invention (e.g., a pharmaceutical compositiondescribed herein) can be administered after the patient has beendetermined to have become resistant to a previously administeredtherapeutic agent. One of ordinary skill in the medical arts willunderstand the phenomenon of resistant cancer, in which a patient'scancer does not respond to treatment at either the beginning oftreatment or during treatment. A resistant cancer may also be calledrefractory, and any treatment method or use described herein may beapplied to a resistant or refractory cancer (e.g., a blood cancer,including any of the types described above, or a proliferative diseasecharacterized by a solid tumor, including any cancer selected from thoselisted above (e.g., an acoustic neuroma, adenocarcinoma, adrenal glandcancer, etc., and in case of any doubt includes a cancer of the breast,intestine, lung, pancreas, prostate, and Ewing's sarcoma)). Accordingly,the methods of treating a patient as described herein can include thestep of identifying or selecting a patient having a cancer that isresistant or refractory to treatment with a prior therapeutic agent,including any of those described herein as an additional/second agent,and a compound of the invention, any specified form thereof, andpharmaceutical compositions containing such a compound or any specifiedform thereof have utility/use in treating such patients. CDK7over-expression has been associated with hormone-receptor positivebreast cancer (HR⁺ breast cancer), triple-negative breast cancer (TNBC),acute myelogenous leukemia (AML), small cell lung cancer (SCLC, e.g.,neuroendocrine SCLC (NE SCLC)), esophageal squamous cell carcinoma,neuroblastoma, high grade gliomas, ovarian cancer, solid tumors, andother hematological malignancies. Accordingly, in the methods oftreatment described herein, the patient can have any of these types ofcancer, and the compounds of the invention, any specified form thereof,and pharmaceutical compositions containing them find utility/use intreating such patients.

In combination therapies of the invention, the compound of Formula (I),(Ia), a species thereof, or a specified form as described herein (e.g.,a pharmaceutically acceptable salt, solvate, stereoisomer, tautomer, orisotopic form thereof) can be administered concurrently with, prior to,or subsequent to, the one or more additional (i.e., distinct)therapeutic agents. Each additional therapeutic agent may beadministered at a dose and/or according to a dosing regimen determinedfor that particular agent (e.g., a dose or dosing regimen approved by aregulatory agency (e.g., the U.S. Food and Drug Administration (FDA) oragencies of similar purpose in other countries), which may be set out inthe product insert accompanying the commercially-supplied agent). Theadditional therapeutic agents may also be administered together witheach other and/or with a compound or composition described herein in asingle dose or administered separately in different doses. Theparticular combination to employ in a regimen will take into account thecompatibility of a compound of the invention with one or more of theadditional/second therapeutic agents and/or the desired therapeuticand/or prophylactic effect to be achieved. In general, it is expectedthat the additional/second therapeutic agents utilized in combinationwill be utilized at levels that do not exceed the levels at which theyare utilized individually. Thus, in some embodiments, the levelsutilized in combination will be lower than those utilized individually.

The second agent can be, but is not limited to, an anti-proliferativeagent, an anti-cancer agent, an anti-diabetic agent, ananti-inflammatory agent, an immunosuppressant agent, or a pain-relievingagent. Such therapeutic agents include small organic molecules such asdrug compounds (e.g., compounds approved by the FDA or the EuropeanMedicines Agency), polypeptides (including nucleoproteins, mucoproteins,glycoproteins, lipoproteins, and antibodies of any target-bindingconfiguration, with the polypeptide being synthetic or naturallyoccurring), carbohydrates (e.g., mono-, oligo-, and polysaccharides),small molecules linked to proteins, steroids, nucleotides, nucleosides,and nucleic acids (e.g., DNAs and RNAs, including any RNA configured forRNAi, regardless of length (e.g., an antisense oligonucleotide orshRNA), lipids, vitamins, and cells (e.g., genetically modified cells(e.g., a genetically engineered immune cell suitable for CAR-T therapy)or cells administered as an allogeneic hematopoietic celltransplantation (HCT)).

In certain embodiments, the additional/second therapeutic agent is aBcl-2 inhibitor such as APG-1252, APG-2575, BP1002 (prexigebersen), theantisense oligonucleotide known as oblimersen (G3139), S55746/BCL201, orvenetoclax (e.g., venetoclax tablets marketed as Venclexta®); a CDK9inhibitor such as alvocidib/DSP-2033/flavopiridol, AT7519, AZD5576,BAY1251152, BAY1143572, CYC065, nanoflavopiridol, NVP2, seliciclib(CYC202), TG02, TP-1287, VS2-370 or voruciclib (formerly P1446A-05); ahormone receptor (e.g., estrogen receptor) degradation agent, such asfulvestrant (e.g., marketed as Faslodex® and others); a Flt3 (FMS-liketyrosine kinase 3) inhibitor such as CDX-301, CG′806, CT053PTSA,crenolanib (e.g., crenolanib besylate), ENMD-2076, FF-10101-01, FLYSYN,gilteritinib (ASP2215), HM43239, lestautinib, ponatinib (e.g., marketedas Iclusig®, previously AP24534), NMS-088, sorafenib (e.g., marketed asNexavar®), sunitinib, pacritinib, pexidartinib/PLX3397, quizartinib,midostaurin (e.g., marketed as Rydapt®), SEL24, SKI-G-801, or SKLB 1028;a PARP inhibitor such as olaparib (e.g., marketed as Lynparza®),rucaparib (e.g., marketed as Rubraca®), talazoparib (e.g., marketed asTalzenna®), veliparib (ABT-888), or niraparib (e.g., marketed asZejula®); a BET inhibitor such as ABBV-075, BAY-299, BAY-1238097,BMS-986158, CPI-0610, CPI-203, FT-1101, GS-5829, GSK-2820151,GSK-525762, I-BET151, I-BET762, INCB054329, JQ1, MS436, OTX015, PFI-1,PLX51107, RVX2135, TEN-010, ZEN-3694, or a compound disclosed in U.S.application Ser. No. 12/810,564 (now U.S. Pat. No. 8,476,260), which ishereby incorporated herein by reference in its entirety; aplatinum-based therapeutic agent such as cisplatin, oxaliplatin (e.g.,marketed as Eloxatin®), nedaplatin, carboplatin (e.g., marketed asParaplatin®), phenanthriplatin, picoplatin, satraplatin (JM216), ortriplatin tetranitrate; a CDK4/6 inhibitor such as BPI-1178, G1T38,palbociclib (e.g., marketed as Ibrance®), ribociclib (e.g., marketed asKisqali®), ON 123300, trilaciclib, or abemaciclib (e.g., marketed asVerzenio®); a MEK inhibitor such as trametinib (e.g., marketed asMekinist®), cobimetinib, or binemetinib; an inhibitor of thePI3K/AKT/mTOR pathway (e.g., gedatolisib); or a phosphoinositide3-kinase (PI3 kinase) inhibitor, optionally of Class I (e.g., Class IA)and/or optionally directed against a specific PI3K isoform. The PI3Kinhibitor can be apitolisib (GDC-0980), idelalisib (e.g., marketed asZydelig®), copanlisib (e.g., marketed as Aliqopa®), duvelisib (e.g.,marketed as Copiktra®), pictilisib, alpelisib (e.g., marketed asPiqray®) or capecitabine.

In other embodiments, the additional/second agent can be capecitabine(e.g., marketed as Xeloda®). In other embodiments, the additional/secondagent can be gemcitabine (combined with a compound of the invention totreat, e.g., TNBC, CRC, SCLC, or a pancreatic cancer (e.g., PDAC)). Inother embodiments, the additional/second agent can be an antimetabolite,such as the pyrimidine analog 5-fluorouracil (5-FU), which may be usedin combination with a compound of Formula (I), (Ia), a species thereof,or a specified form thereof, and one or more of leucovorin,methotrexate, or oxaliplatin. In other embodiments, theadditional/second agent can be an aromatase inhibitor, such asexemestane or anastrasole.

APG-1252 is a dual Bcl-2/Bcl-xL inhibitor that has shown promise inearly clinical trials when patients having SCLC or another solid tumorwere dosed between 10-400 mg (e.g., 160 mg) intravenously twice weeklyfor three weeks in a 28-day cycle (see Lakhani et al., J. Clin. Oncol.36:15_suppl, 2594, and ClinicalTrials.gov identifier NCT03080311).APG-2575 is a Bcl-2 selective inhibitor that has shown promise inpreclinical studies of FL and DLBCL in combination with ibrutinib (seeFang et al., AACR Annual Meeting 2019, Cancer Res. 79(13 Suppl):Abstract No. 2058) and has begun clinical trials as a single-agenttreatment for patients with blood cancers; in a dose escalation study,patients are given 20 mg, once daily, by mouth, for four consecutiveweeks as one cycle. Escalations to 50, 100, 200, 400, 600 and 800 mg areplanned to identify the MTD (see ClinicalTrials.gov identifierNCT03537482). BP1002 is an uncharged P-ethoxy antisenseoligodeoxynucleotide targeted against Bcl-2 mRNA that may have feweradverse effects than other antisense analogs and has shown promise ininhibiting the growth of human lymphoma cell lines inclubated withBP1002 for four days and of CJ cells (transformed FL cells) implantedinto SCID mice (see Ashizawa et al., AACR Annual Meeting 2017, CancerRes. 77(13 Suppl): Abstract No. 5091). BP1002 has also been administeredin combination with cytarabine (LDAC) to patients having AML (seeClinicalTrials.gov identifier NCT04072458). S55746/BCL201 is an orallyavailable, selective Bcl-2 inhibitor that, in mice, demonstratedanti-tumor efficacy in two blood cancer xenograft models (Casara et al.,Oncotarget 9(28):20075-88, 2018). A phase I dose-escalation study wasdesigned to administer film-coated tablets containing 50 or 100 mg ofS55746, in doses up to 1500 mg, to patients with CLL or a B cell NHLincluding FL, MCL, DLBCL, SLL, MZL, and MM (see ClinicalTrials.govidentifier NCT02920697). Venetoclax tablets have been approved fortreating adult patients with CLL or SLL and, in combination withazacytidine, or decitabine, or low-dose cytarabine, for treatingnewly-diagnosed AML in patients who are at least 75 years old or whohave comorbidities that preclude the use of intensive inductionchemotherapy. Dosing for CLL/SLL can follow the five-week ramp-upschedule and dosing for AML can follow the four-day ramp-up, bothdescribed in the product insert, together with other pertinentinformation (see also U.S. Pat. Nos. 8,546,399; 9,174,982; and9,539,251, which are hereby incorporated by reference in theirentireties). Alvocidib was studied in combination withcytarabine/mitoxantrone or cytarabine/daunorubicin in patients with AML,with the details of administration being available at ClinicalTrials.govwith the identifier NCT03563560 (see also Yeh et al., Oncotarget6(5):2667-2679, 2015, Morales et al., Cell Cycle 15(4):519-527, 2016,and Zeidner et al., Haematologica 100(9):1172-1179, 2015). AT7519 hasbeen administered in a dose escalation format to eligible patientshaving refractory solid tumors. While there was some evidence ofclinical activity, the appearance of QTc prolongation precluded furtherdevelopment at the dose schedule described by Mahadevan et al. (J. Clin.Oncol. ASCO Abstract No. 3533; see also Santo et al., Oncogene29:2325-2336, 2010, describing the preclinical activity of AT7519 inMM). AZD5576 induced apoptosis in breast and lung cancer cell lines atthe nanomolar level (see Li et al., Bioorg. Med. Chem. Lett.27(15):3231-3237, 2017) and has been examined alone and in combinationwith acalabrutinib for the treatment of NHL (see AACR 2017 Abstract No.4295). BAY1251152 was the subject of a phase I clinical trial tocharacterize the MTD in patients with advanced blood cancers; the agentwas infused weekly in 21-day cycles (see ClinicalTrials.gov identifierNCT02745743; see also Luecking et al., AACR 2017 Abstract No. 984).Voruciclib is a clinical stage oral CDK9 inhibitor that represses MCL-1and sensitizes high-risk DLBCL to BCL2 inhibition. Dey et al.(Scientific Reports 7:18007, 2017) suggest that the combination ofvoruciclib and venetoclax is promising for a subset of high-risk DLBCLpatients (see also ClinicalTrials.gov identifier NCT03547115).Fulvestrant has been approved for administration to postmenopausal womenwith advanced hormone receptor (HR)-positive, HER2-negative breastcancer, with HR-positive metastatic breast cancer whose diseaseprogressed after treatment with other anti-estrogen therapies, and incombination with palbociclib (Ibrance®). Fulvestrant is administered byintramuscular injection at 500 or 250 mg (the lower dose beingrecommended for patients with moderate hepatic impairment) on days 1,15, and 29, and once monthly thereafter (see the product insert foradditional information; see also U.S. Pat. Nos. 6,744,122; 7,456,160;8,329,680; and 8,466,139, each of which are hereby incorporated byreference herein in their entireties). Ponatinib has been administeredin clinical trials to patients with CML or ALL (see ClinicalTrials.govidentifiers NCT0066092072, NCT012074401973, NCT02467270, NCT03709017,NCT02448095, NCT03678454, and NCT02398825) as well as solid tumors, suchas biliary cancer and NSCLC (NCT02265341, NCT02272998, NCT01813734,NCT02265341, NCT02272998, NCT01813734, NCT02265341, NCT02272998,NCT01813734, NCT01935336, NCT03171389, and NCT03704688; see also thereview article by Tan et al., Onco. Targets Ther. 12:635-645, 2019).Additional information regarding the dosing regimen can be found in theproduct insert; see also U.S. Pat. Nos. 8,114,874; 9,029,533; and9,493,470, each of which is hereby incorporated by reference herein inits entirety. Sorafenib has been approved for the treatment of kidneyand liver cancers, AML, and radioactive iodine resistant advancedthyroid cancer, and a clinical trial was initiated in patients withdesmoid-type fibromatosis (see ClinicalTrials.gov identifierNCT02066181). Information regarding dosage can be found in the productinsert, which advises administration of two, 400 mg tablets twice daily;see also U.S. Pat. Nos. 7,235,576; 7,351,834; 7,897,623; 8,124,630;8,618,141; 8,841,330; 8,877,933; and 9,737,488, each of which is herebyincorporated by reference herein in its entirety. Midostaurin has beenadministered to patients having AML, MDS, or systemic mastocytosis, andhas been found to significantly prolong survival of FLT3-mutated AMLpatients when combined with conventional induction and consolidationtherapies (see Stone et al., ASH 57th Annual Meeting, 2015 and Galloglyet al., Ther. Adv. Hematol. 8(9):245-251, 2017; clin see also theproduct insert, ClinicalTrials.gov identifier NCT03512197, and U.S. Pat.Nos. 7,973,031; 8,222,244; and 8,575,146, each of which is herebyincorporated by reference herein in its entirety. Alpelisib is a kinaseinhibitor indicated in combination with fulvestrant for the treatment ofpostmenopausal women, and men, with HR+/HER2−/PIK3CA-mutated, advancedor metastatic breast cancer as detected by an FDA-approved testfollowing progression on or after an endocrine-based regimen. Therecommended dose is 300 mg (two 150 mg tablets) taken orally once dailywith food, which, as for all chemotherapeutic agents, may beinterrupted, reduced, or discontinued to manage adverse reactions.Paclitaxel is supplied as a nonaqueous solution intended for dilutionwith a suitable parenteral fluid prior to intravenous infusion. Underthe brand name Taxol®, it is supplied in 30 mg, 100 mg, and 300 mg vialsand can be used in a combination therapy described herein to treat avariety of cancers, including those of the bladder, breast, esophagus,fallopian tube or ovary, lung, skin (melanoma), and prostate.Palbociclib has been approved for use in HR+/HER2− advanced ormetastatic breast cancer at a recommended dose of 125 mg daily, bymouth. It can be used with a compound of the invention either alone orin combination with an aromatase inhibitor or fulvestrant. Theinformation provided here and publicly available can be used to practicethe methods and uses of the invention. In case of doubt, the inventionencompasses combination therapies that require a compound of theinvention or a specified form thereof and any one or moreadditional/second agents, which may be administered at or below a dosagecurrently approved for single use (e.g., as described above), to apatient as described herein. Triplet combinations include a compound ofFormula (I), (Ia), a species thereof, or a specified form thereof with:alpelisib and fulvestrant or alpelisib and a taxane (for, e.g., treatingNSCLC).

In one embodiment, the method of treatment includes administering, to apatient who is suffering from a sarcoma (e.g., an osteosarcoma,rhabdomyosarcoma, or Ewing's sarcoma), a therapeutically effectiveamount of a compound described herein (e.g., a compound of Formula I or(Ia) (e.g., Compound 100, 101, or 102)) or a specified form thereof anda therapeutically effective amount of a PARP inhibitor (e.g., olaparib(e.g., marketed as Lynparza®), rucaparib (e.g., marketed as Rubraca®),talazoparib (e.g., marketed as Talzenna®), veliparib (ABT-888), orniraparib (e.g., marketed as Zejula®). Such “uses” are also within thescope of the present invention.

Also encompassed by the invention are kits (e.g., pharmaceutical packs).The kits may be used for preventing and/or treating any of the diseasesset forth herein. The kits provided may comprise a pharmaceuticalcomposition or compound of the present invention; and a container (e.g.,a vial, ampule, bottle, syringe, and/or dispenser package, or othersuitable container) for storing, reconstituting, and/or administeringthe compound or composition. In some embodiments, provided kits mayoptionally further include a second container comprising apharmaceutical excipient for dilution or suspension of thepharmaceutical composition or compound of the invention. In someembodiments, the pharmaceutical composition or compound provided in thecontainer and the second container are combined to form one unit dosageform. In some embodiments, provided kits may optionally further includea second or third container comprising an additional therapeutic agentto be administered in combination with the pharmaceutical composition orcompound of the invention. The kit can also include any type ofparaphernalia useful in administering the active agent(s) containedtherein (e.g., tubing, syringes, needles, sterile dressings, tape, andthe like). In certain embodiments, the kits are useful in preventingand/or treating a proliferative disease in a subject. In certainembodiments, the kits further include instructions for administering thecompound, or a pharmaceutically acceptable salt, solvate, hydrate,tautomer, isotopically and labeled derivative thereof, or apharmaceutical composition thereof, to a subject to prevent and/or treata proliferative disease.

In yet another aspect, the present invention provides the compounds ofFormula I or Formula Ia and pharmaceutically acceptable salts, solvates,and hydrates thereof for use in the treatment of a proliferative diseasein a subject. In certain embodiments, provided by the invention are thecompounds described herein, and pharmaceutically acceptable salts andcompositions thereof, for use in the treatment of a proliferativedisease in a subject. In certain embodiments, provided by the inventionare the compounds described herein, and pharmaceutically acceptablesalts and compositions thereof, for use in inhibiting cell growth. Incertain embodiments, provided by the invention are the compoundsdescribed herein, and pharmaceutically acceptable salts and compositionsthereof, for use in inducing apoptosis in a cell. In certainembodiments, provided by the invention are the compounds describedherein, and pharmaceutically acceptable salts and compositions thereof,for use in inhibiting transcription.

EXAMPLES

The compounds described herein can be prepared from readily availablestarting materials and according to the synthetic protocols describedbelow. Alternatively, one of ordinary skill in the art may readilymodify the disclosed protocols. For example, it will be appreciated thatwhere process conditions (e.g., reaction temperatures, reaction times,mole ratios of reactants, solvents, pressures, etc.) are given, otherprocess conditions can also be used.

Additionally, and as will be apparent to one of ordinary skill in theart, protecting groups may be used to prevent certain functional groupsfrom undergoing undesired reactions. The choice of a suitable protectinggroup for a particular functional group as well as suitable conditionsfor protection and deprotection are well known in the art. For example,numerous protecting groups and guidance for their introduction andremoval are disclosed by Greene et al. (Protecting Groups in OrganicSynthesis, Second Edition, Wiley, New York, 1991, and references citedtherein).

Example 1: Synthesis of Benzyl (2R,5R)-5-amino-2-methyl-piperidine-1-carboxylate and benzyl (2S,5S)-5-amino-2-methyl-piperidine-1-carboxylate Step 1: Benzyl5-(tert-butoxycarbonylamino)-2-methyl-piperidine-1-carboxylate

To a solution containing commercially available racemic trans tert-butylN-(6-methyl-3-piperidyl)carbamate (5 g, 23.33 mmol, 1 eq.) andNaHCO₃(13.72 g, 163.32 mmol, 7 eq) in tetrahydrofuran (THF; 50 mL) andH₂O (50 mL), we added CbzCl (5.97 g, 35.00 mmol, 4.98 mL, 1.5 eq)dropwise at 0° C. The mixture was stirred at 15° C. for 2 hours thenpoured into water (50 mL) and extracted with ethyl acetate (EtOAc; 50mL×3). The combined organic layer was washed with brine (50 mL×3), driedover Na₂SO₄, and filtered. The filtrate was concentrated under reducedpressure, and the residue was purified by medium pressure liquidchromatography (MPLC; SiO₂, PE:EtOAc=5:1 to 1:1) to give the titlecompound as a yellow solid (9.7 g, 18.04 mmol, 77.32% yield, 64.8%purity).

Step 2: Benzyl (2R, 5R)-5-amino-2-methyl-piperidine-1-carboxylate andbenzyl (2S, 5S)-5-amino-2-methyl-piperidine-1-carboxylate

To a mixture of racemic trans benzyl5-(tert-butoxycarbonylamino)-2-methyl-piperidine-1-carboxylate (9.7 g,27.84 mmol, 1 eq) in EtOAc (100 mL) we added HCl/EtOAc (15 mL, 4 M), andthe mixture was stirred at 15° C. for 1 hour. We then filtered themixture and collected the filter cake. The solid was dissolved inmethanol (MeOH; 15 mL) and the pH was adjusted to 9 using a stronglyacidic cation exchange resin (here, AMBERLYST® A21) before the mixturewas filtered and the filtrate was concentrated. The residue wasseparated by supercritical fluid chromatography (SFC; column: marketedby Daicel as CHIRALCEL® (chemicals for use in chromatography) ODH (250mm×30 mm, 5 μm); mobile phase: [0.1% NH₃.H₂O MeOH]; B %: 28%-28%, 16min) to afford title compound 1 (1.9 g, SFC: Rt=2.264 min, 93.2% ee,peak 1) and title compound 2 (1.9 g, SFC: Rt=2.593 min, 98.6% ee, peak2), both as light yellow solids. Peak 1 is structure 3. Peak 2 isstructure 4.

Example 2: Synthesis of 7-dimethylphosphoryl-3-[2-[[(3S,6S)-6-methyl-3-piper-idyl]amino]-5-(trifluoromethyl)pyrimidin-4-yl]-1H-indole-6-carbonitrile(Compound 100) Step 1: Benzyl (2S,5S)-5-[[4-(7-chloro-6-cyano-1H-indol-3-yl)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-2-methyl-piperidine-1-carboxylate

We stirred a mixture of7-chloro-3-[2-chloro-5-(trifluoromethyl)pyrimidin-4-yl]-1H-indole-6-carbonitrile(0.81 g, 2.27 mmol, 1 eq), benzyl (2S,5S)-5-amino-2-methyl-piperidine-1-carboxylate (732.20 mg, 2.95 mmol, 1.3eq) and N,N-diisopropylethylamine (DIEA or DIPEA; 879.41 mg, 6.80 mmol,1.19 mL, 3 eq) in N-methyl-2-pyrrolidone (NMP; 8 mL) at 140° C. for 1hour. The reaction mixture was diluted with H₂O (100 mL) and extractedwith EtOAc (50 mL×2). The combined organic layers were washed with brine(100 mL×2), dried over Na₂SO₄, filtered, and concentrated under reducedpressure to give a residue that was purified by column chromatography(SiO₂, petroleum ether/ethyl acetate=10:1 to 4:1) to afford titlecompound as a yellow solid (1.1 g).

Step 2: Benzyl (2S,5S)-5-[[4-(6-cyano-7-dimethylphosphoryl-1H-indol-3-yl)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-2-methyl-piperidine-1-carboxylate

We prepared a mixture of benzyl(2S,5S)-5-[[4-(7-chloro-6-cyano-1H-indol-3-yl)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-2-methyl-piperidine-1-carboxylate (1.05 g, 1.85mmol, 1 eq), methylphosphonoylmethane (720.17 mg, 9.23 mmol, 5 eq),K₃PO₄ (783.45 mg, 3.69 mmol, 2 eq), Pd(OAc)₂ (41.43 mg, 184.54 μmol, 0.1eq), xantphos (C₃₉H₃₂OP₂; 106.78 mg, 184.54 μmol, 0.1 eq) anddimethylformamide (DMF; 10 mL) in a microwave sealed tube, degassed it,and purged it with N₂ (×3). The mixture was then stirred at 150° C. for1 hour in microwave. The reaction mixture was diluted with H₂O (100 mL)and extracted with ethyl acetate (EtOAc; 50 mL×3). The combined organiclayers were washed with brine (150 mL×2), dried over Na₂SO₄, filtered,and concentrated under reduced pressure to give a residue that wepurified by column chromatography (SiO₂, petroleum ether/ethylacetate=10:1 to 1:1) to afford the title compound as a yellow oil (490mg).

Step 3: 7-dimethylphosphoryl-3-[2-[[(3S,6S)-6-methyl-3-piperidyl]amino]-5-(trifluoromethyl)pyrimidin-4-yl]-1H-indole-6-carbonitrile

To a solution of benzyl(2S,5S)-5-[[4-(6-cyano-7-dimethylphosphoryl-1H-indol-3-yl)-5-(trifluoromethyl)pyrimidin-2-yl]amino]-2-methyl-piperidine-1-carboxylate(440 mg, 720.64 μmol, 1 eq) in EtOAc (5 mL), we added Pd/C (200 mg, 10%purity) under N₂. We degassed the suspension under vacuum, purged itwith H₂ several times, then stirred the mixture under H₂ (15 psi) at 20°C. for 3 hours before filtering it. The filtrate was concentrated togive a residue we purified by prep-HPLC (high performance liquidchromatography; neutral condition) to yield the title compound as awhite solid (142.2 mg).

The reaction was combined with another reaction in 50 mg scale forpurification by liquid chromatography mass spectrometry (LCMS). LCMS:ET6034-1492-P1C: (M+H+): 477.1 @2.572 (10-80% ACN (acetonitrile) in H₂O4.5 minutes). ¹H NMR (400 MHz, DMSO (dimethylsulfoxide)-d₆) δ 8.74 (brd, J=7.89 Hz, 1H), 8.65-8.44 (m, 2H), 8.17 (br d, J=15.35 Hz, 1H), 7.84(br t, J=8.11 Hz, 1H), 7.67 (br t, J=7.02 Hz, 1H), 3.81 (br s, 1H), 3.10(br d, J=11.40 Hz, 1H), 2.45-2.38 (m, 1H), 2.02 (d, J=13.59 Hz, 8H),1.64 (br d, J=11.40 Hz, 1H), 1.49-1.34 (m, 1H), 1.11 (br d, J=10.96 Hz,1H), 0.97 (br d, J=5.70 Hz, 3H)

Example 3: Synthesis of (S)-6,6-dimethylpiperidin-3-amine

We dissolved (S)-tert-butyl (6-oxopiperidin-3-yl)carbamate (1.00 g, 4.67mmol) (Tetrahedron Letters, 36:8205, 1995) in THF (47 mL) and cooled thesolution to −10° C. Zirconium (IV) chloride (2.61 g, 11.22 mmol) wasadded, and the mixture was stirred for 30 minutes at this temperature. Amethylmagnesium bromide solution (3M in ether, 20.25 mL, 60.75 mmol) wasadded, and the reaction mixture was allowed to slowly warm up to roomtemperature, at which it was stirred overnight. The solution wasquenched with 30% aqueous NaOH, diluted with EtOAc, filtered, and thenextracted 3 times with EtOAc. The organics were combined, dried oversodium sulfate, filtered, and concentrated in vacuo to provide the crudeproduct as a yellow oil that was used without purification. The oil wasdissolved in dichloromethane (DCM; 47 mL) and trifluoroacetic acid (TFA;3.58 mL, 46.73 mmol) was added. We stirred the reaction mixture at roomtemperature for 16 hours, concentrated it in vacuo and co-evaporated ita few times with DCM to provide the crude title compound as a brown oil,which we used in the next step without further purification.

Example 4: Synthesis of(S)-7-(dimethylphosphoryl)-3-(2-((6,6-dimethylpiperidin-3-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)-1H-indole-6-carbonitrile(Compound 101) Step 1: 7-Bromo-1H-indole-6-carboxylic Acid

We stirred a solution of vinylmagnesium bromide (1.0 M in THF (159 mL,159 mmol) at −78° C. and added to it, dropwise, over a period of 1 hour,a solution of 2-bromo-3-nitrobenzoic acid (10.0 g, 39.8 mmol) in THF(159 mL). The reaction mixture was allowed to reach room temperature andwas stirred at that temperature overnight. The reaction mixture was thenpoured over saturated aqueous ammonium chloride (150 mL) and acidifiedto a pH 2, using aqueous 1M HCl. We extracted the crude product withEtOAc (3×200 mL), dried the extract over sodium sulfate, filtered it,and concentrated it in vacuo. The residue was then triturated in DCM(100 mL) and dried overnight with a flow of air to provide the titlecompound as a light brown solid (7.58 g, 31.58 mmol, 79% yield).

Step 2: 7-Bromo-1H-indole-6-carboxamide

We stirred a solution of 7-bromo-1H-indole-6-carboxylic acid (6.58 g,27.4 mmol) in DMF (54.8 mL) at 0° C. and added 1,1′-carbonyldiimidazole(CDI; 8.89 g, 54.8 mmol) to it portion wise. The mixture was stirred for5 minutes, and the intermediate was observed by LCMS. We then addedNH₄OH (39.5 mL, 274 mmol) at 0° C., and the solution was stirred for 5minutes. The reaction was quenched with saturated aqueous ammoniumchloride (25 mL) and saturated aqueous sodium chloride (25 mL) thendiluted with 2-methyltetrahydrofuran (MeTHF; 50 mL). We separated thephases and washed the organic layer again with saturated aqueousammonium chloride (25 mL) and saturated aqueous sodium chloride (25 mL).The organic layer was then dried over sodium sulfate, filtered, andconcentrated in vacuo to provide the title compound, which was carriedover to the next step assuming the quantitative yield.

Step 3: 7-Bromo-1H-indole-6-carbonitrile

We added Et₃N (triethylamine; 44.1 mL, 315 mmol) to a suspension of7-bromo-1H-indole-6-carboxamide (7.53 g, 31.5 mmol) in DCM (315 mL) at0° C. and stirred the resulting orange solution at that temperatureuntil we obtained a homogeneous solution. MsCl (12.2 mL, 157 mmol) wasthen added dropwise, and the solution was stirred at 0° C. for 5minutes. We diluted the mixture with ethyl acetate and washed it withsaturated aqueous sodium bicarbonate before extracting the aqueous layertwice more with ethyl acetate. The organic layers were combined, washedwith brine, dried over sodium sulfate, filtered, and concentrated invacuo. The residue was purified by filtering it through a pad of silica(eluting with ethyl acetate) to provide the title compound as a brownsolid (5.80 g, 26.24 mmol, 83% yield).

Step 4:7-Bromo-3-(2-chloro-5-(trifluoromethyl)pyrimidin-4-yl)-1H-indole-6-carbonitrile

We added AlCl₃ (1.83 g, 13.6 mmol) to a solution of2,4-dichloro-5-trifluoromethylpyrimidine (3.66 mL, 27.2 mmol) in1,2-dichloroethane (DCE; 36.2 mL) and stirred the resulting suspensionat 80° C. for 30 minutes. We added 7-bromo-1H-indole-6-carbonitrile(2.00 g, 9.05 mmol) to the mixture and stirred the resulting redsolution at 80° C. until full conversion (4 hours). The reaction mixturewas then diluted with MeTHF (100 mL) and washed with water (100 mL). Theaqueous layer was extracted with 2-MeTHF (100 mL), and the organicextracts were combined, dried over sodium sulfate, filtered, andconcentrated in vacuo. Formation of two possible regioisomers wasobserved in a ratio of 3:1 (desired/undesired). We purified the residueby reverse phase chromatography on C18 (MeCN (acetonitrile) in water, 15to 80% gradient) to provide the title compound as a beige solid (1.51 g,3.76 mmol, 42% yield). ¹H NMR (500 MHz, DMSO) δ 13.00 (brs, 1H), 9.17(s, 1H), 8.35 (d, J=8.4 Hz, 1H), 8.16 (d, J=2.6 Hz, 1H), 7.71 (d, J=8.4Hz, 1H).

Step 5:(S)-7-Bromo-3-(2-((6,6-dimethylpiperidin-3-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)-1H-indole-6-carbonitrile

We dissolved7-bromo-3-(2-chloro-5-(trifluoromethyl)pyrimidin-4-yl)-1H-indole-6carbonitrile (200 mg, 0.498 mmol), (S)-6,6-dimethylpiperidin-3-amine(95.8 mg 0.747 mmol), and DIPEA (174 μL, 0.996 mol) in NMP (4 mL) thenstirred the reaction mixture at 130° C. in an oil bath until fullconversion (3 hours). The mixture was cooled to room temperature, loadeddirectly onto a C18 column and purified by reverse phase chromatography(MeCN with 0.1% FA (formic acid) in water also containing 0.1% FA, 0 to100% gradient). The title compound was obtained as a beige solid (245mg, 0.497 mmol, quantitative yield).

Step 6:(S)-7-(dimethylphosphoryl)-3-(2-((6,6-dimethylpiperidin-3-yl)amino)-5-(trifluoromethyl)-pyrimidin-4-yl)-1H-indole-6-carbonitrile

We combined(S)-7-bromo-3-(2-((6,6-dimethylpiperidin-3-yl)amino)-5-(trifluoromethyl)-pyrimidin-4-yl)-1H-indole-6-carbonitrile(180.0 mg, 0.365 mmol), Xantphos (21.5 mg, 36.5 μmol), palladium (II)acetate (4.14 mg, 18.2 μmol), and KPO₄ (85.2 mg, 0.401 mmol) in a 2.5 mLmicrowave vial under nitrogen. Dimethylphosphine oxide (73 mg, 0.912mmol) was dissolved in anhydrous DMF (1 mL), and the solution wasdegassed before combining with the other reactants in a microwave vial.The sealed vial with the reaction mixture was then submitted to heat ina microwave reactor at 150° C. for 45 minutes. The reaction mixture wascooled to room temperature, loaded directly onto a C18 column, andpurified by reverse phase chromatography (MeCN in aqueous 10 mM ammoniumformate pH 3.8, 15 to 35% gradient). The title compound was obtained asan off-white solid (76 mg, 0.155 mmol, 42% yield).

Example 5: Synthesis of (3S)-1-benzyl-5, 5-dimethyl-piperidin-3-amine

Step 1: Methyl (2S)-5-oxopyrrolidine-2-carboxylate

We added SOCl₂ (215.62 g, 1.81 mol, 131.47 mL, 2 eq) to a solution of(2S)-5-oxopyrrolidine-2-carboxylic acid (117 g, 906.18 mmol, 1 eq) inMeOH (500 mL) at 0° C. The mixture was stirred at 18° C. for 1 hourbefore the reaction mixture was concentrated. We diluted the residuewith EtOAc (1000 mL) and TEA (triethylamine; 150 mL) and filtered thesolid that was formed. The filtrate was evaporated to afford the titlecompound as a light yellow oil (147 g, crude) to be used directly in thenext step without any further purification.

Step 2: (S)-1-tert-butyl 2-methyl 5-oxopyrrolidine-1,2-dicarboxylate

To a solution of methyl (2S)-5-oxopyrrolidine-2-carboxylate (147 g, 1.03mol, 1 eq), DMAP (4-dimethylaminopyridine; 15.06 g, 123.24 mmol, 0.12eq) and TEA (259.80 g, 2.57 mol, 357.35 mL, 2.5 eq) in EtOAc (500 mL) weadded tert-butoxycarbonyl tert-butyl carbonate (291.37 g, 1.34 mol,306.71 mL, 1.3 eq), dropwise, at 0° C. The mixture was then stirred at20° C. for 16 hours. We then washed the reaction mixture with HCl (0.5M, 1000 mL), saturated NaHCO₃ (1000 mL), brine (1500 mL), dried it overNa2SO4, and filtered and concentrated it under reduced pressure to givea residue that was then purified by re-crystallization from methyltert-butyl ether (MTBE; 250 mL). The reaction mixture was filtered andevaporated to afford the title compound as a white solid (2 batchesobtained; Batch 1: 108 g, 100% HPLC purity; Batch 2: 53 g, 90% ¹H NMRpurity).

Step 3: (S)-1-tert-butyl 2-methyl4,4-dimethyl-5-oxopyrrolidine-1,2-dicarboxylate

We added LiHMDS (lithium hexamethyldisilazide; 1 M, 172.66 mL, 2.1 eq),dropwise, to a solution of (S)-1-tert-butyl 2-methyl 5-oxopyrrolidine-1,2-dicarboxylate (20 g, 82.22 mmol, 1 eq) in THF (500 mL) at −78° C.under N₂ atmosphere. After addition, the mixture was stirred at thattemperature for 30 minutes before we added CH₃I (35.01 g, 246.65 mmol,15.36 mL, 3 eq), dropwise, at −78° C. under N₂ atmosphere. The resultingmixture was stirred at 20° C. for 2.5 hours. The reaction mixture wasdiluted with saturated aqueous NH₄Cl (1000 mL) and extracted with EtOAc(300 mL×3). The combined organic layers were washed with brine (500 mL),dried over Na₂SO₄, filtered, and concentrated under reduced pressure togive a residue that was purified by MPLC (SiO₂, PE: EtOAc=4: 1-3:1) toafford the title compound as a light yellow solid (8 g, 25.95 mmol,31.56% yield, 88% purity).

Step 4: tert-butylN-[(1S)-4-hydroxy-1-(hydroxymethyl)-3,3-dimethyl-butyl]carbamate

To a solution of (S)-1-tert-butyl 2-methyl 4,4-dimethyl-5-oxopyrrolidine-1,2-dicarboxylate (4.3 g, 15.85 mmol, 1 eq)in THF (35 mL) we added NaBH₄ (1.80 g, 47.55 mmol, 3 eq), by portions,at 0° C. under N₂. After addition, EtOH (ethanol; 8.25 g, 179.09 mmol,10.47 mL, 11.3 eq) was added dropwise at 0° C. The resulting mixture wasstirred at 20° C. for 16 hours then poured into saturated aqueous NH₄Cl(250 mL) and extracted with EtOAc (100 mL×3). The combined organiclayers were washed with brine (250 mL), dried over Na₂SO₄, filtered andconcentrated under reduced pressure to afford the title compound as acolorless oil (3.67 g, crude), which was used directly in the next stepwithout any further purification

Step 5:[(2S)-2-(tert-butoxycarbonylamino)-4,4-dimethyl-5-methylsulfonyloxy-pentyl]methanesulfonate

To a solution of tert-butyl N-[(1S)-4-hydroxy-1-(hydroxymethyl)-3,3-dimethyl-butyl]carbamate (3.67 g,14.84 mmol, 1 eq) and TEA (6.01 g, 59.35 mmol, 8.26 mL, 4 eq) in EtOAc(25 mL) we added methanesulfonyl chloride (5.10 g, 44.52 mmol, 3.45 mL,3 eq), dropwise, at 0° C. The resulting mixture was stirred at 20° C.for 12 hours then poured into H₂O (200 mL). EtOAc (50 mL×3) was used toextract the product. The organic layer was washed with brine (30 mL),dried over Na₂SO₄, filtered and evaporated to afford the title compoundas a colorless oil (6.06 g crude) that was used directly in the nextstep without any further purification.

Step 6: Tert-butyl N-[(3S)-1-benzyl-5,5-dimethyl-3-piperidyl]carbamate

A flask was fitted with [(2S)-2-(tert-butoxycarbonylamino)-4,4-dimethyl-5-methyl-sulfonyloxypentyl] methanesulfonate (6.06 g, 15.02mmol, 1 eq), phenylmethanamine (5.15 g, 48.06 mmol, 5.24 mL, 3.2 eq) anddimethoxyethane (DME; 50 mL). We heated the reaction mixture to 70° C.for 16 hours then poured it into H₂O (40 mL). DCM (40 mL×3) was used toextract the product. The organic layer was washed with brine (30 mL),dried over Na₂SO₄, filtered and evaporated to afford the crude product,which was purified twice by MPLC (SiO₂, PE: EtOAc=20:1-10:1) to affordthe title compound as a colorless oil (580 mg, 1.49 mmol, 9.91% yield,81.7% purity).

Step 7: (3S)-1-benzyl-5, 5-dimethyl-piperidin-3-amine

A flask was fitted with tert-butyl N-[(3 S)-1-benzyl-5,5-dimethyl-3-piperidyl] carbamate (300 mg, 942.05 μmol, 1 eq) inHCl/EtOAc (15 mL). The mixture was stirred at 25° C. for 1 hour, afterwhich some white precipitate formed. We filtered the mixture, and thecake was washed by EtOAc (5 mL), collected and dried over vacuum toafford the title compound as a white solid (220 mg, 738.23 μmol, 78.36%yield, 85.5% purity, HCl) as a white solid to be used directly in thenext step.

Example 6: Synthesis of(S)-7-(dimethylphosphoryl)-3-(2-((5,5-dimethylpiperidin-3-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)-1H-indole-6-carbonitrile(Compound 102) Step 1:(S)-3-(2-((1-benzyl-5,5-dimethylpiperidin-3-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)-7-bromo-1H-indole-6-carbonitrile

We dissolved 7-bromo-3-(2-chloro-5-(trifluoromethyl)pyrimidin-4-yl)1H-indole-6-carbonitrile (168 mg, 0.418 mmol),(S)-1-benzyl-5,5-dimethylpiperidin-3-amine (128 mg, 0.585 mmol), andDIPEA (221 μL, 1.26 mmol) in NMP (2 mL). We stirred the reaction mixtureat 130° C. in an oil bath until full conversion (4 hours). The mixturewas cooled to room temperature, diluted with EtOAc and washed withsaturated aqueous LiCl. The organic layer was separated, dried oversodium sulfate, filtered, and concentrated in vacuo to provide the crudetitle compound (240 mg, 0.41 mmol, quant. yield), which was used in thenext step without further purification.

Step 2:(S)-3-(2-((1-benzyl-5,5-dimethylpiperidin-3-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)-7-(dimethylphosphoryl)-1H-indole-6-carbonitrile

We combined(S)-3-(2-((1-benzyl-5,5-dimethylpiperidin-3-yl)amino)-5-(trifluoro-methyl)pyrimidin-4-yl)-7-bromo-1H-indole-6-carbonitrile(240 mg, 0.411 mmol), Xantphos (24.3 mg, 41.1 mmol), palladium (H)acetate (4.66 mg, 20.6 μmol), and K₃PO₄ (96.0 mg, 0.452 mmol) in a 2.5mL microwave vial under nitrogen. Dimethylphosphine oxide (39.2 mg,0.494 mmol) was dissolved in anhydrous DMF (1 mL), and the solution wasdegassed before combining with the other reactants in a microwave vial.The sealed vial with the reaction mixture was then submitted to heat ina microwave reactor at 145° C. for 45 minutes. The reaction mixture wasthen cooled to room temperature, diluted with 2-MeTHF and washed withsaturated aqueous NaHCO₃ and brine. The organic layer was separated,dried over sodium sulfate, filtered, and concentrated in vacuo beforethe residue was purified by reverse phase chromatography on C18 (MeCN inaqueous 10 mM ammonium formate pH 3.8, 0 to 100% gradient). The titlecompound was obtained as a pale brown oil (58.0 mg, 0.10 mmol, 24%yield).

Step 3:(S)-7-(dimethylphosphoryl)-3-(2-((5,5-dimethylpiperidin-3-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)-1H-indole-6-carbonitrile

Under a nitrogen atmosphere, to a stirring solution of(S)-3-(2-((1-benzyl-5,5-dimethylpiperidin-3-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)-7-(dimethylphosphoryl)-1H-indole-6-carbonitrile(58.0 mg, 0.10 mmol) in EtOH (12.5 mL), we added Pd/C 10% w/w (1.1 mg,0.01 mmol) and Boc₂O (di-t-butyl decarbonate; 65.5 mg, 0.30 mmol). Thereaction mixture was evacuated and back-filled with nitrogen (×3) beforebeing filled with hydrogen. The reaction mixture was then stirred atroom temperature overnight under hydrogen atmosphere. After 16 hours, weobserved an incomplete conversion and therefore filtered the reactionmixture through a pad of CELITE® and concentrated it under reducedpressure. The reaction was then repeated with the residue as describedabove. After almost complete consumption of starting material (48hours), the reaction mixture was filtered through a pad of CELITE® andconcentrated in vacuo to provide the crude product, which was engaged inthe next step. Thus, the obtained oil was re-dissolved in DCM (5 mL),and TFA (0.23 mL, 3.0 mmol) was added. The reaction mixture was stirredat room temperature overnight. The mixture was then concentrated invacuo, and the residue was purified by reverse phase chromatography onC18 (MeCN in aqueous 10 mM ammonium formate pH 3.8, 0 to 100% gradient)to provide the title compound as a white solid (11.11 mg, 0.023 mmol,23% yield over two steps).

Example 7: Inhibition of CDK Kinase Activity

We assayed some compounds for inhibition of CDK7, CDK9, CDK12, and CDK2activity at Biortus Biosciences (Jiangyin, Jiangsu Province, P.R. ofChina) using kinase assays for each CDK developed with a Caliper/LabChipEZ Reader (Perkin Elmer, Waltham, Mass.). These assays measure theamount of phosphorylated peptide substrate produced as a fraction of thetotal peptide following an incubation period at 27° C. with thefollowing components: test compounds (variable concentrations from 10 μMdown to 0.508 nM in a series of 3-fold serial dilutions), active CDKprotein (with the indicated cyclin, listed below for each CDK), ATP (ateither the K_(m) concentrations listed below for each CDK/cyclin or 2 mMATP), and substrate peptide (listed below) in the following buffer:2-(N-morpholino)ethanesulfonate (MES buffer, 20 mM), pH 6.75, 0.01%(v/v) Tween 20 detergent, 0.05 mg/mL bovine serum albumin (BSA), and 2%DMSO.

Specifically, the CDK7 inhibition assay used CDK7/Cyclin H/MAT1 complex(6 nM) and “5-FAM-CDK7tide” peptide substrate (2 μM, synthesizedfluorophore-labeled peptide with the sequence5-FAM-YSPTSPSYSPTSPSYSPTSPSKKKK (SEQ ID NO: 1), where “5-FAM” is5-carboxyfluorescein) with 6 mM MgCl₂ in the buffer composition listedabove where the apparent ATP K_(m) for CDK7/Cyclin H/MAT1 under theseconditions is 50 μM. The CDK9 inhibition assay used CDK9/Cyclin Ticomplex (8 nM) and “5-FAM-CDK9tide” peptide substrate (2 μM, synthesizedfluorophore-labeled peptide with the sequence: 5-FAM-GSRTPMY-NH2 (SEQ IDNO:2), where 5-FAM is defined above and NH₂ signifies a C-terminal amidewith 10 mM MgCl₂ in the buffer composition listed above. The CDK12inhibition assay used CDK12 (aa686-1082)/Cyclin K complex (50 nM) and“5-FAM-CDK9tide” (2 μM) as defined above, with 2 mM MgCl₂ in the buffercomposition above. The CDK2 inhibition assay used CDK2/Cyclin E1 complex(0.5 nM) and “5-FAM-CDK7tide” (2 μM) as defined above, with 2 mM MgCl₂in the buffer composition listed above.

The incubation period at 27° C. for each CDK inhibition assay was chosensuch that the fraction of phosphorylated peptide product produced ineach assay, relative to the total peptide concentration, wasapproximately 20% (±5%) for the uninhibited kinase (35 minutes for CDK7,35 minutes for CDK2, 3 hours for CDK12, and 15 minutes for CDK9). Incases where the compound titrations were tested and resulted ininhibition of peptide product formation, these data were fit to producebest-fit IC₅₀ values. The best-fit IC₅₀ values at K_(m) ATP for eachCDK/Cyclin, except for CDK7/Cyclin H/MAT1, were used to calculate K_(i)values, or the apparent affinity of each inhibitor for each CDK/Cyclinfrom the kinase activity inhibition assay, according to theCheng-Prusoff relationship for ATP substrate-competitive inhibition(Cheng and Prusoff, Biochem. Pharmacol., 22(23)3099-3108, 1973), with acorrection term for inhibitor depletion due to the enzyme concentration(Copeland, “Evaluation of Enzyme Inhibitors in Drug Discover: A Guidefor Medicinal Chemists and Pharmacologists,” Second Edition, March,2013; ISBN: 978-1-118-48813-3):

${IC_{50}} = {{K_{i}( {1 + \frac{\lbrack{Substrate}\rbrack}{K_{m}}} )} + \frac{\lbrack{Enzyme}\rbrack}{2}}$

Due to tight-binding inhibition and the limits of the CDK7/Cyclin H/MAT1assay, instead of calculating the apparent K_(i) values for eachinhibitor, the K_(d), or direct compound binding affinity, was measuredusing surface plasmon resonance (SPR) as described below.

Example 8: CDK7/Cyclin H Surface Plasmon Resonance (SPR) Assay Method

We measured binding kinetics and affinities of selected compounds to theCDK7/Cyclin H dimer using a Biacore T200 surface plasmon resonance (SPR)instrument (GE Healthcare). The dimer was amine-coupled to a CM5 sensorchip at pH 6.5 in 10 mM MES buffer at a concentration of 12.5 μg/mL witha flow rate of 10 μL/min. Target protein was immobilized on two flowcells for 12-16 seconds to achieve immobilized protein levels of 200-400Response Units.

Compounds were titrated from 0.08-20 nM in a 9-step, 2-fold serialdilution in 10 mM HEPES buffer at pH 7.5 with 150 mM NaCl, 0.05%Surfactant P20, and 0.0002% DMSO. Each compound concentration cycle wasrun at 100 μL/min with 70 second contact time, 300 second dissociationtime, 60 second regeneration time with 10 mM glycine pH 9.5, and 400second stabilization time. For each compound, 0 nM compound controls andreference flow-cell binding were subtracted to remove background andnormalize data. Compound titrations were globally fit by Biacore T200Evaluation Software (GE Healthcare) using kinetics mode. Best-fit valuesfor compound binding on-rate (k_(on)) and dissociation off-rate(k_(off)) for CDK7/Cyclin H were determined and these values were usedto calculate the compound affinity (K_(d)) for CDK7/Cyclin H using thefollowing equation:

${K_{d}(M)} = \frac{k_{off}( s^{- 1} )}{k_{on}( {M^{- 1}s^{- 1}} )}$

Compound selectivity for CDK7 over CDK2, CDK9, or CDK12 was determinedbased on the ratios of K_(i) values for the off-target CDKs relative tothe direct compound binding K_(d) for CDK7 measured by SPR according to:

${Selectivity} = \frac{K_{i,{{off}\mspace{11mu}{target}}}}{K_{d,{{CDK}\; 7}}}$The inhibitory and dissociation constants and selectivity of theindicated compounds (three compounds of the invention and fourcomparators) against CDK2, CDK7, CDK9, and CDK12 are shown in the tableof FIG. 1. As can be seen, each of the compounds of the invention is atleast 1300-fold and up to 40,000-fold more specific for CDK7 than forthe other CDKs tested.

Example 9: Inhibition of Cell Proliferation (Compounds 100-102)

The HCC70 cell line was derived from human TNBC, and we testedrepresentative compounds of the invention, at different concentrations(from 4 μM to 126.4 pM; 0.5 log serial dilutions), for their ability toinhibit the proliferation of those cells. More specifically, we testedthe same compounds tested above for CDK7 selectivity (the structures ofwhich are shown in FIG. 1), and we used the known CDK inhibitorsdinaciclib (or N-((1 S,3R)-3-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)cyclohexyl)-5-((E)-4-(dimethylamino)but-2-enamido)picolinamide)and triptolide as positive controls. The cells were grown inATCC-formulated RPMI-1640 medium (ATCC 30-2001) supplemented with 10%fetal bovine serum (FBS), at 37° C. in a humidified chamber in thepresence of 5% CO₂. We conducted proliferation assays over a 72-hourtime period using a CyQUANT® Direct Cell Proliferation Assay (LifeTechnologies, Chicago, Ill. USA) according to the manufacturer'sdirections and utilizing the reagents supplied with the kit. The resultsof the assay are shown in the Table below.

Compound HCC70 EC₅₀ (nM) Compound 100 0.98 Compound 101 5.6 Compound 1022.1 Comparator 1 0.53 Comparator 2 260 Comparator 3 24 Comparator 4 110

Example 10: Tumor Growth Inhibition in Patient-Derived Xenograft (PDX)Models

Tumor growth inhibition was evaluated in estrogen receptor-positivebreast cancer (ER+BC) PDX models selected in vivo for resistance to theCDK4/6 inhibitor palbociclib (ST1799, n=1) or resistance to bothpalbociclib and fulvestrant (ST941, n=1). Dosing was initiated whentumors were 100-200 mm³. Mice were treated with either Compound 101, QD(6 mg/kg, once daily, by mouth); fulvestrant, SC (2.5 mg/kg, once weeklydosing, by subcutaneous injection); palbociclib, QD (50 mpk, once daily,by mouth) or in combination of Compound 101 (6 mg/kg, once daily, bymouth) and fulvestrant (2.5 mg/kg, once weekly, by subcutaneousinjection) over the course of 28 days, followed by 21 days ofobservation. Tumor growth inhibition (TGI) was calculated on the lastday of dosing using the formula: TGI=(V_(c1)−V_(t1))/(V_(c0)−V_(t0)),where V_(c1) and V_(t1) are the mean volumes of control and treatedgroups at the time of tumor extraction, while V_(c0) and V_(t0) are thesame groups at the start of dosing.

In the palbociclib-resistant ER+BC PDX (ST1799) model, the combinationof Compound 101 and fulvestrant induced significant TGI (89%) with noevident tumor regrowth up to 21 days after dosing cessation,distinguishing the observed effects from Compound 101 (83%), fulvestrant(60%) or palbociclib (21%) when administered as single agents.Additionally, the combination of Compound 101 and fulvestrant wassuperior to the standard of care (SOC) combination of palbociblib andfulvestrant (75%). In a palbociclib and fulvestrant double-resistantER+BC PDX model (ST941), Compound 101 administered as a single agentresulted in 33% TGI and fulvestrant and palbociclib as single agents orfulvestrant and palbociclib in combination had no activity. In contrast,the combination of Compound 101 and fulvestrant demonstrated significantTGI (68%; p<0.0001 vs fulvestrant as a single agent), suggestingre-sensitization to fulvestrant.

FIG. 2 illustrates the TGI results from the palbociclib resistant HR+BCPDX model ST1799, and FIG. 3 illustrates the TGI results from thepalbociclib and fulvestrant resistant HR+BC PDX model ST941. We alsoobserved TGI in four additional PDX models; BR5010 (modeling TNBC),LU5178 (modeling small cell lung cancer (SCLC)), OV15398 (modeling highgrade serous ovarian cancer (HGSOC)), and ST390 (modeling pancreaticductal adenocarcinoma (PDAC)). In the TNBC model, Compound 101 wasorally administered to tumor-bearing NOD/SCID mice at 10 mg/kg QD or 5mg/kg BID for 21 days. In the SCLC and HGSOC models, Compound 101 wasorally administered to tumor-bearing NOD/SCID mice at 3 mg/kg BID for 21days. In the PDAC model, Compound 101 was orally administered totumor-bearing NOD/SCID mice at 6 mg/kg QD. In the TNBC, SCLC, and HGSOCmodels, tumor volume was measured during the treatment period and for anadditional 21 days after treatment ceased. The % TGI observed at the endof treatment (day 21) was calculated as: 1−[(Mean TV Compound 101 @EOT−Mean TV Compound 101 @ Day 0)/(Mean TV Veh @ EOT−Mean TV Veh @ Day0)]×100. The % regression was calculated as: (Mean TV Compound 101 @EOT)/(Mean TV Compound 101 @Day 0)×100. The same calculations were usedfor end of study (day 42). The results are shown in FIG. 4. Theseresults demonstrate deep and sustained TGI, including regressions, atwell tolerated doses, in a variety of tumor types. Dose-dependenttranscriptional responses in xenograft tissue were observed within 4hours of dosing and were sustained for 24 hours. Similar TGI was seenwhen the same total dose was administered either QD or BID in the TNBCPDX model, suggesting that the effect was AUC or C_(min) driven.Moreover, the TGI observed in SCLC (in the LU5178 PDX model) had notbeen observed in previous studies with a covalent CDK7 inhibitor (datanot shown). Regarding the model of PDAC, we found Compound 101 induced100% TGI over the time examined (˜28 days) at a dose well below the MTD:at day 21, tumor volume was ˜1,250 mm³ in vehicle-treated mice but onlyabout 250 mm³ in Compound 1-treated mice (6 mg/kg QD, PO). WhileCompound 101 could achieve 100% TGI at sub-MTD doses in the tested PDACPDX tumors, a covalent CDK7 inhibitor achieved only modest TGI at itsMTD (40 mg/kg BIW, by IV administration, with evident body weight loss(8.4%) and necrosis at the injection site; data not shown).

One of ordinary skill in the art will recognize or be able to ascertainusing no more than routine experimentation many equivalents to thespecific embodiments described herein. The embodiments described indetail herein are not intended to limit the scope of the invention. Oneof ordinary skill in the art will appreciate that various changes andmodifications to the embodiments described may be made without departingfrom the spirit or scope of the present invention, as defined in thefollowing claims.

Example 11. In Vitro Studies of Compound 101 in Combination with VariousSecond Agents

In the studies described here, cancer cell lines from HR+ breast cancers(lines T47D; PIK3CA p.H1047R, MCF7; PIK3CA p.E545K), SCLC, (NCI-H1048)and CRCs (lines RKO; BRAF p.V600E, SW480; KRAS p.G12V) were grown to 70%confluency in their media of preferences based on the manufacturerrecommendations. In the SCLC cell line (NCI-H1048), Compound 101 wastested in combination with SOC chemotherapy agents gemcitabine (a DNAsynthesis inhibitor) and carboplatin (a DNA damage agent). In a CRC cellline (RKO; BRAF p.V600E), Compound 101 was tested in combination withSOC chemotherapy agent oxaliplatin (a DNA damage agent). Additionally,in CRC, Compound 101 was tested in combination with the selective MAPKpathway inhibitor trametinib in two CRC cell lines harboring MAPKpathway alterations; RKO (BRAF p.V600E mutant) and SW480 (KRAS p.G12Vmutant). Compound 101 was tested in combination with the SOC agentcapecitabine (an antimetabolite) in HR+MCF-7 cells. In the HR+ celllines MCF7 and T47D, which have activating mutations in the PIK3CAkinases, Compound 101 was tested in combination with the PIK3CAselective inhibitor alpelisib. On the day of assay, cells were liftedand counted using the Countess II FL (Life Technologies). Using anautomated dispenser (here, Multidrop™ Combi Reagent Dispenser), 50 μL ofpreferred cell media containing 20,000-50,000 cells/ml was distributedinto black 384-well Nunc plates (Thermo) and allowed to adhere overnightprior to compound addition. Compound arrays were distributed to 384 wellassay plates using Synergy Plate Format with an HP D300e DigitalDispenser (HP). Compound 101 and other TEST agents were dissolved inDMSO to make a stock solution that allowed for more accurate dispensing.However, due to solubility and reactivity, platinum agents weredissolved in water with an addition of 0.03% Tween-20 to allow fordispensing with digital printer. Compounds were plated in each quadrantof a 384-well plate in quadruplicate. Each quadrant contained test wellswith combination of SY-1365 and carboplatin or oxaliplatin (TEST/testagent) as well as single agent columns, and vehicle wells.

Compound 101 was plated in across from left to right in a high to lowconcentration (8 columns), and the varying concentrations of carboplatinor oxaliplatin (TEST) plated in synergy wells from top to bottom (7rows). Concentrations were selected to cover the full isobologram ofactivity based on activity of single agents. Single agents were platedin dose in two columns, with a third separate column of justDMSO/vehicle treated wells. A separate plate for each cell line wasseeded to allow for determination of a “Time Zero”/“Day Zero” number ofcells to parse the differential cytostatic vs cytotoxic effects. On theday compounds were added, viability of the time zero plate wasdetermined to identify growth inhibition from cell killing effects.

After addition of compound, cell plates were incubated for 5 days in a37° C. incubator. Cell viability was evaluated using CellTiter-Glo® 2.0(Promega) following manufacturer protocols. Data was analyzed inCalcuSyn utilizing the median effect principle of presented byChou-Talalay and visualized using GraphPad Prism Software. Keyparameters assessed were combination index and dose reduction index.

We found the combination of Compound 101 with SOC chemotherapy(gemcitabine or carboplatin in SCLC, oxaliplatin in CRC, or capecitabinein HR+ breast cancer) showed synergy and was superior to either agentalone. The combination of Compound 101 with the targeted agenttrametinib, a selective MAPK pathway inhibitor approved for thetreatment of BRAF p.V600E mutant melanoma and NSCLC, show significantsynergy in BRAF p.V600E mutant CRC as well as in KRAS p.G12V mutant CRC,which harbors a different mutation within the MAPK pathway. Thecombination of Compound 101 with the targeted agent alpelisib, aselective PIK3CA inhibitor approved for the treatment of PIK3CA mutantHR+BC, showed significant synergy in both HR+ cell lines representingthe two most common activating mutation of PIK3CA (p.E545K andp.H1047R). All synergy was determined using CalcuSyn utilizing themedian effect principle of presented by Chou-Talalay and visualizedusing GraphPad Prism Software. Combination effect is reflected by shiftin IC50 of Compound 101 with addition of carboplatin or oxaliplatin orincreased antiproliferative effect with lower amounts of either singleagent. This is visualized in the isobolograms of FIG. 5, where pointsbelow the diagonal line reflect synergy.

Example 12. Deep and Sustained Responses to Compound 101 in TNBC, HGSOC,and SCLC PDX Models

We evaluated TGI in 12 different PDX models (Crown Biosciences) invarious tumor indications with PDXs representing SCLC (n=5; LU5180,LU5178, LU5192, LU5173, LU5210), TNBC (n=4; BR5010, BR1458, BR5399,BR10014) and HGSOC (n=3; OV15398, OV5392, OV15631). Dosing was initiatedwhen tumors were 150-300 mm³. Mice were treated with either Compound101, QD (6 or 10 mg/kg once daily, by mouth) or BID (3 or 5 mg/kg twicedaily, by mouth) over the course of 21 days, followed by 21 days ofobservation. TGI was calculated on the last day of dosing using theformula: TGI=(V_(c1)−V_(t1))/(V_(c0)−V_(t0)), where V_(c1) and V_(t1)are the mean volumes of control and treated groups at the time of tumorextraction, while V_(c0) and V_(t0) are the same groups at the start ofdosing.

To perform whole exome sequencing (WES), we isolated DNA from passagematched tumors using DNeasy® Blood and Tissue Kit via manufacturerprotocol and sent it to Wuxi Aptec for WES using Agilent's SureSelectXTHuman All Exon V6 kit. Samples were sequenced to a depth of ˜300×. Readswere trimmed to remove adapter sequences via Skewer (v0.2.1). Reads werethen mapped and further processed using Sentieon tools: BWA, DeDup,Realigner, and QualCal (v201808.03). Variants were called usingSentieon's Haplotyper tool, and initial annotations were performed usingEnsembl's Variant Effect Predictor (VEP, release_96.2). FATHMM-MLK wasalso used to annotate variant effects. Variants that met the followingqualifications were included in sample characterizations: (1) variant islocated in a protein-coding gene; (2) variant affects protein sequenceor results in a frameshift; (3) missense mutations are classified asdamaging by SIFT, PolyPhen, or FATHMM-MLK (>0.75); (4) variant allelefrequency is >10%. Copy-number (CN) variation across capture regionswere called using CNVkit (v0.9.1), and CNs for individual genes werecalculated by using the mean CN across its capture regions. For modelLU5210 mutation/CNV data was made available from WES data provided bythe PDX vendor (Crown Biosciences Inc.).

At these doses, Compound 101 induced at least 50% TGI at the end of the21-day dosing period in all models. In a subset of models (58%, 7/12),Compound 101 responses were deep (>95% TGI or regression) and sustained,with no evidence of tumor regrowth for 21 days after treatmentdiscontinuation (see FIG. 6). Compound 101 was well tolerated, with noevident body weight loss at all once-daily doses tested, indicating thatthe MTD is above 10 mg/kg once daily in tumor-bearing mice. Deep andsustained responses were observed in each indication tested.

What is claimed is:
 1. A compound of the formula:


2. A pharmaceutical composition comprising a therapeutically effectiveamount of the compound of claim 1 and a pharmaceutically acceptablecarrier.
 3. The pharmaceutical composition of claim 2, wherein thecomposition is formulated for oral administration.
 4. The pharmaceuticalcomposition of claim 3, wherein the composition is formulated as anaqueous or non-aqueous solution or suspension.
 5. The pharmaceuticalcomposition of claim 3, wherein the composition is formulated as atablet or capsule.
 6. The pharmaceutical composition of claim 2, whereinthe composition is formulated in unit dosage form.
 7. The pharmaceuticalcomposition of claim 3, wherein the composition is formulated in unitdosage form.
 8. The pharmaceutical composition of claim 2, wherein thecomposition is formulated for administration in liquid form.
 9. Thepharmaceutical composition of claim 3, wherein the composition isformulated for administration in liquid form.
 10. The pharmaceuticalcomposition of claim 2, wherein the composition is formulated foradministration in solid form.
 11. The pharmaceutical composition ofclaim 3, wherein the composition is formulated for administration insolid form.
 12. The pharmaceutical composition of claim 2, wherein thepharmaceutically acceptable carrier comprises an inert diluent, adispersing or granulating agent, a surface active agent or emulsifier, adisintegrating agent, a binding agent, a preservative, a bufferingagent, or an emulsifier.
 13. The pharmaceutical composition of claim 2,wherein the pharmaceutically acceptable carrier comprises acellulose-based substance.
 14. The pharmaceutical composition of claim5, wherein the carrier comprises lactose and/or corn starch.
 15. Apharmaceutically acceptable salt of the compound of claim
 1. 16. Thepharmaceutically acceptable salt of claim 15, wherein the salt is anacid addition salt.
 17. The pharmaceutically acceptable salt of claim16, wherein the acid addition salt is formed with lactic acid,hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid,perchloric acid, acetic acid, oxalic acid, maleic acid, tartaric acid,citric acid, succinic acid, or malonic acid.
 18. A pharmaceuticalcomposition comprising a therapeutically effective amount of thepharmaceutically acceptable salt of claim 15 and a pharmaceuticallyacceptable carrier.
 19. The pharmaceutical composition of claim 18,wherein the composition is formulated for oral administration.
 20. Thepharmaceutical composition of claim 19, wherein the composition isformulated as an aqueous or non-aqueous solution or suspension.
 21. Thepharmaceutical composition of claim 19, wherein the composition isformulated as a tablet or capsule.
 22. The pharmaceutical composition ofclaim 18, wherein the composition is formulated in unit dosage form. 23.The pharmaceutical composition of claim 18, wherein the pharmaceuticallyacceptable carrier is a sterile liquid.
 24. The pharmaceuticalcomposition of claim 18, wherein the composition is formulated foradministration in liquid form.
 25. The pharmaceutical composition ofclaim 19, wherein the composition is formulated for administration inliquid form.
 26. The pharmaceutical composition of claim 18, wherein thecomposition is formulated for administration in solid form.
 27. Thepharmaceutical composition of claim 19, wherein the composition isformulated for administration in solid form.
 28. The pharmaceuticalcomposition of claim 18, wherein the pharmaceutically acceptable carriercomprises an inert diluent, a dispersing or granulating agent, a surfaceactive agent or emulsifier, a disintegrating agent, a binding agent, apreservative, a buffering agent, or an emulsifier.
 29. Thepharmaceutical composition of claim 18, wherein the pharmaceuticallyacceptable carrier comprises a cellulose-based substance.
 30. Thepharmaceutical composition of claim 21, wherein the carrier compriseslactose and/or corn starch.